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Abstract: Primary mitochondrial diseases (PMD) refer to a group of severe, often inherited genetic
conditions due to mutations in the mitochondrial genome or in the nuclear genes encoding for
proteins involved in oxidative phosphorylation (OXPHOS). The mutations hamper the last step
of aerobic metabolism, affecting the primary source of cellular ATP synthesis. Mitochondrial
diseases are characterized by extremely heterogeneous symptoms, ranging from organ-specific
to multisystemic dysfunction with different clinical courses. The limited information of the
natural history, the limitations of currently available preclinical models, coupled with the large
variability of phenotypical presentations of PMD patients, have strongly penalized the development
of effective therapies. However, new therapeutic strategies have been emerging, often with promising
preclinical and clinical results. Here we review the state of the art on experimental treatments for
mitochondrial diseases, presenting “one-size-fits-all” approaches and precision medicine strategies.
Finally, we propose novel perspective therapeutic plans, either based on preclinical studies or currently
used for other genetic or metabolic diseases that could be transferred to PMD.
Keywords: mitochondria; mitochondrial DNA; mitochondrial disorders; pharmacological therapy;
gene therapy; precision medicine
1. Genetics of Mitochondrial Diseases
Primary mitochondrial disorders (PMD) are a group of rare diseases affecting approximately
1 in 4300 live birth and causing progressive, incurable defects often resulting in premature death.
PMD are characterized by a high genetic, biochemical, and clinical complexity that arise from the
dysfunction of the oxidative phosphorylation (OXPHOS), the essential, final pathway for aerobic
metabolism [1]. Such impairment is caused by mutations in genes encoding for proteins involved in
mitochondrial respiratory chain (MRC) biogenesis, (i.e., subunits of MRC complexes, assembly factors,
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or post-assembly quality controllers), or by mutations in genes involved in other mitochondrial
functions, including fission and fusion machinery, mitochondrial DNA (mtDNA) maintenance,
heme biosynthesis, and iron/sulfur metabolism, among others [2].
Each mitochondrion contains several mitochondrial DNA (mtDNA) molecules, the abundance of
which spans from hundreds to thousands of copies per cell, depending on the tissue type. For years,
it was trusted that in physiological conditions, all mtDNA molecules have the same sequence,
a condition known as homoplasmy. When mutations in mtDNA occur, wild type and mutant molecules
coexist in the same cell/organ, a condition known as heteroplasmy. However, recent deep resequencing
analysis has shown that low-level mtDNA heteroplasmy is extremely common in humans, and, at very
low levels (0.5–1%), heteroplasmy seems to be a universal finding [3].
MtDNA mutations could affect any gene encoding the 13 core subunits of the MRC complexes,
the 22 mitochondrial tRNAs, or the two rRNAs. They can include point mutations, either homo- or
heteroplasmic, and (invariably heteroplasmic) large-scale rearrangements. Heteroplasmic mutations
lead to different clinical phenotypes, such as Leigh syndrome (LS) [4], myoclonic epilepsy with ragged
red fibers (MERRF) [5], mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
(MELAS) [6], and neurogenic weakness, ataxia, and retinitis pigmentosa (NARP) [7]. The central
disease entity associated with homoplasmic mtDNA mutations is Leber’s hereditary optic neuropathy
(LHON) [8]. Mutations in the same gene can lead to different clinical presentation; for instance,
mitochondrial phenotypes described in patients with MT-ATP6 mutations span from maternally
inherited Leigh syndrome and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP)[9],
to Charcot–Marie–Tooth disease [10], late-onset hereditary spastic paraplegia-like disorder [11],
and MERRF-like phenotype [12]. Rearrangements (single deletions or duplications) of mtDNA
are responsible for sporadic progressive external ophthalmoplegia (PEO), Kearns–Sayre syndrome
(KSS) [13], and Pearson’s syndrome [14,15].
There are approximately 1500 predicted mitochondrial genes, that if mutated could lead to
mitochondrial dysfunction [16], and so far, more than 300 have been linked to mitochondrial
disorders [17,18]. Advanced diagnostic technologies, like next-generation sequencing, are leading to a
rapid escalation in the discoveries of novel disease-causing genes. Therefore, a further, widely accepted,
genetic classification of PMD is based on the function of the protein products encoded by the
mutated genes and includes (i) structural subunits of complexes I-IV, and ATP synthase complex
F0F1; (ii) assembly factors of complexes I-IV, and ATP synthase complex F0F1; (iii) factors performing
or regulating replication, expression, and stability of mtDNA; (iv) proteins related to mitochondrial
biogenesis or indirectly associated to OXPHOS; (v) proteins of the execution pathways, such as
fission/fusion and apoptosis; (vi) proteins involved in the biosynthesis and metabolism of cofactors;
or (vii) proteins involved in the biosynthesis and metabolism of mitochondrial membrane lipids.
The mitochondrial membrane potential (∆Ψm) generated by proton-pumping Complexes I,
III, and IV, is essential not only for the energy storage but also for the elimination of disabled
mitochondria [19]. Genetic defects affecting these respiratory complexes often lead to dysfunctional
∆Ψm with significant consequences to the viability of the cells. However, a comprehensive description
of clinical features and genetic causes of PMD is beyond the scope of this manuscript; please refer
to [20,21] for an exhaustive list.
Despite significant advances in understanding the pathophysiology, the extremely varied
phenotype–genotype relationship of PMD [1] (Figure 1) has strongly limited the development of
effective therapies. Currently, no approved cure exists for most of them, and existing treatments are
focused on relieving complications. However, in recent decades, significant signs of progress have
been reported. In this manuscript, we will review the most substantial advances in the treatment of
PMD and discuss future therapeutic perspectives.
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Figure 1. Clinical features of mitochondrial disorder: PMD arise from the dysfunction of the oxidative 
phosphorylation (OXPHOS) and are characterized by a high genetic, biochemical, and clinical 
complexity that hinder the prediction of disease progression and the development of therapeutic 
strategies. 
2. Therapeutic Approaches to Treat Mitochondrial Disorders 
In this manuscript, we choose to classify the current treatments as (i) “one-size-fits-all” 
strategies, which could, in principle, be used to treat different PMD, regardless the underlying genetic 
mutation; and (ii) “precision medicine” approaches, aimed at treating a specific PMD with a specific 
mutation or a peculiar metabolic hallmark. The reader should note, however, that such categorization 
does not act as unconditional rule, since some exceptions are indeed possible. 
The ‘one-size-fits-all’ strategies include symptomatic interventions, mainly diet, exercise, 
exposure to hypoxia, and pharmacological therapy, which is based on drugs aiming at (i) inducing 
mitochondrial biogenesis; (ii) stimulating the pathway of nitric oxide synthase; (iii) increasing ATP 
synthesis; (iv) improving antioxidant defense; (v) enhancing the mitochondrial quality control 
pathway by stimulating dynamics (fission/fusion events) and degradation of damaged mitochondria 
(autophagy); (vi) targeting cardiolipin. Recent advances in understanding the underlying 
pathophysiology of several PMD have made possible the development of a ‘precision medicine’ 
approach in some cases. Specialized therapies include: (i) supplementation of nucleotides; (ii) 
replacing defective mtDNA in the oocyte; (iii) supplementation of exogenous mitochondria; (iv) 
gene- and cell-replacement therapies; (v) scavenging of poisoning metabolites; (vi) organ 
transplantation; (vii) mtDNA editing. Appendix Table A1 summarizes the most relevant discussed 
approaches, distinguishing those that are currently only at preclinical level from therapies advanced 
in clinical trials or exploited in compassionate use. 
3. “One-Size-Fits-All” Approaches 
3.1. Physical Exercise 
Although mitochondrial patients’ clinical features are highly variable, neurological involvement 
is often present, best described as neuromuscular defect, including muscle weakness, exercise 
intolerance, and fatigue. The molecular defect in patients with mitochondrial myopathies (MM) 
commonly involves the mitochondrial genome, with either single, large-scale deletions, or point 
mutations, resulting in mosaicism of MRC-competent and MRC-affected muscle fibers [22]. Given 
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2. Therapeutic Approaches to Treat Mitochondrial Disorders
In this manuscript, we choose to classify the current treatments as (i) “one-size-fits-all” strategies,
which could, in principle, be used to treat different PMD, regardless the underlying genetic mutation;
and (ii) “precision medicine” approaches, aimed at treating a specific PMD with a specific mutation or
a peculiar metabolic hallmark. The reader should note, however, that such categorization does not act
as unconditional rule, since some exceptions are indeed possible.
The ‘one-size-fits-all’ strategies include symptomatic interventions, mainly diet, exercise,
exposure to hypoxia, and pharmacological therapy, which is based on drugs aiming at (i) inducing
mitochondrial biogenesis; (ii) stimulating the pathway of nitric oxide synthase; (iii) increasing ATP
synthesis; (iv) improving antioxidant defense; (v) enhancing the mitochondrial quality control pathway
by stimulating dynamics (fission/fusion events) and degradation of damaged mitochondria (autophagy);
(vi) targeting cardiolipin. Recent advances in understanding the underlying pathophysiology of
several PMD have made possible the development of a ‘precision medicine’ approach in some cases.
Specialized therapies include: (i) supple entation of nucleotides; (ii) replacing defective mtDNA in
the oocyte; (iii) supplementation of exogenous mitochondria; (iv) gene- and cell-replacement therapies;
(v) scavenging of poisoning metabolites; (vi) organ transplantation; (vii) mtDNA editing. Appendix A
Table A1 summarizes the most relevant discussed approaches, distinguishing those that are currently
only at preclinical level from therapies advanced in clinical trials or exploited in compassionate use.
3. “One-Size-Fits-All” Approaches
3.1. Physical Exercise
Although mitochondrial patients’ clinical features are highly variable, neurological involvement is
often present, b st described as neuromuscular defect, including muscle weakness, exercise intolerance,
and fatigue. The molecular defect in patients with mitochondrial myopathies (MM) commonly involves
the mitochondrial genome, with either single, large-scale deletions, or point mutations, resulting in
mosaicism of MRC-competent and MRC-affected muscle fibers [22]. Given the well-established positive
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effects of physical exercise on healthy subjects, exercise training has been suggested as an approach
to improve physical capacity and quality of life. The rationale of endurance training is based on
three fundamental aspects: (i) to counteract adverse physiological effects of deconditioning caused
by habitual avoidance of activities, provoking the symptoms of fatigue; (ii) to ameliorate the disease
process by increasing mitochondrial biogenesis and MRC activity in skeletal muscle; and, in case of
mtDNA mutations/deletions; (iii) to stimulate the induction of muscle satellite cells, which have low or
undetectable levels of mtDNA mutations, shifting the wild-type mtDNA templates to mature muscle.
Endurance exercise is a potent inducer of mitochondrial biogenesis [23], not only in skeletal
muscle but also in the brain [24]. Exercise triggers mitochondrial proliferation through inducing the
peroxisome proliferator-activated receptor-γ (PPAR-γ) coactivator 1α (PGC-1α), which is the master
transcriptional regulator modulating mitochondrial biogenesis [25]. Endurance training also activates
PGC-1β, AMP-dependent kinase (AMPK), p38γ MAPK, and hypoxia-inducible factors (HIFs) [26],
contributing to the extensive metabolic and molecular remodeling that leads to the preservation of
aerobic fitness and muscle strength. Also, physical activity upregulates endothelial nitric oxide synthase
(eNOS) gene expression with the consequent increase of nitric oxide (NO) production, which in turn
induces mitochondrial biogenesis and cell glucose uptake in skeletal and cardiac muscle [27,28]. Please
refer to Section 3.6 for an extensive description of the molecular mechanisms.
Muscle satellite cells are dormant, committed myogenic cells reactivated as needed for muscle
growth and repair. Since mutant mtDNA molecules are often undetectable in satellite cells
cultured from affected muscles of MM patients [29,30], the stimulations of the proliferation and
incorporation of satellite cells into existing myofibers through exercise training have been proposed as
a method for normalizing the skeletal muscle mtDNA genotype in MM patients, with encouraging
results [31,32]. Favorable effects of physical exercise have been demonstrated in preclinical models
of PMD. Prolonged endurance exercise conferred muscular protection and prevented early mortality
in the transgenic PolG mouse model, harboring a defect in the proofreading-exonuclease activity of
mitochondrial polymerase gamma [33]. Significantly, such effects were not limited to skeletal muscle
but also involved other organs, including brain, blood, and heart. Exercise training significantly
improved aerobic fitness, OXPHOS activity, and muscle strength in the Harlequin mutant mouse,
a model of complex I (CI) deficiency due to a proviral insertion in the apoptosis-inducing factor
(Aif ) gene. Significant activation of the mTORC1-mediated anabolic pathway in skeletal muscle was
reported upon training [34]. Exercise training also remodeled MRC complexes organizations in skeletal
muscle of healthy humans, increasing the amount of MRC complexes organized into supercomplexes
(SC) and promoting the redistribution of CI from SC I+III2 to SC I+III2+IVn and of complex III (CIII)
and complex IV (CIV) from free forms or SC I+III2 into more functional SC species, such as the fully
assembled SC I+III2+IVn [35].
These and other findings [36,37] supported endurance training as a therapeutic strategy for patients
affected by MM, and beneficial effects have been reported in open-label clinical studies. Twelve-week
supervised rehabilitation endurance training increased maximal oxygen uptake, work output,
minute ventilation, endurance performance, walking distance in shuttle walking test, peripheral muscle
strength, and improved clinical symptoms in patients with MM [38]. Prolonged physical exercise
increased VO2MAX, citrate synthase activity, and mtDNA quantity in muscle biopsies of MM patients;
these beneficial effects partially reverted after deconditioning [39]. Taivassalo and co-workers obtained
similar training and detraining results, but they did not see an effect on mtDNA amount [40].
Endurance training also promoted heteroplasmic shifting, reducing the relative proportion of mutant
to wild-type mtDNA in patients with heteroplasmic mtDNA deletions and point mutations [41,42].
However, other studies reported a trend toward the preferential proliferation of mutant genomes in MM
patients with heteroplasmic mtDNA mutations following prolonged aerobic training, despite enhanced
muscle OXPHOS, raising some concern proposing endurance training as a treatment option [43].
Finally, other studies suggested that muscle from MM patients may be exposed to greater levels
of oxidative stress during the training, given to the reduced expression of DNA repair machinery,
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and reduced aconitase activity, despite the induction of the antioxidant enzyme Mn-superoxide
dismutase (MnSOD) [44].
Therefore, physical exercise could ameliorate clinical conditions and OXPHOS activity in MM
patients; however, further studies are needed to investigate whether a link between heteroplasmic shift
towards mutant mtDNA and the level of physical activity may exist.
3.2. Dietary Approaches
Epilepsy is a common feature of PMD. The ketogenic diet (KD) is a high-fat (≈90%),
low-carbohydrate diet that allows the generation of ketone bodies (KB) in the liver through
mitochondrial β-oxidation of fatty acids. KB are then metabolized to acetyl-CoA, which feeds
the tricarboxylic acid (TCA) cycle, thus serving as an alternative energy source for brain, heart,
and skeletal muscle. KD can control seizures with an unclear mechanism [45], and for this reason,
it has been proposed for PMD patients who have epilepsy. A comparative study reported that 7 out
of 14 children with intractable epilepsy and various MRC complex defects treated with KD became
seizure-free, while others had important seizure reduction, spanning 50% and 90% [46]. In another
study, KD produced clinical progress, including seizure reduction and global functional improvement
in 75% of the treated patients [47]. No severe side effects were reported in both studies.
Besides the curative effects on seizure, KD has also been proposed in patients suffering from
inborn errors of pyruvate dehydrogenase complex (PDC) [48], given the alternative production of
acetyl-CoA from KB rather than pyruvate. Patients treated with KD showed increased longevity
and improved mental development [48]. KD was also proposed to treat CI defects, as it could
promote the mitochondrial respiration through complex II (CII) activity and the oxidation of FADH2,
therefore bypassing the inactive CI [49,50].
KB also increased OXPHOS genes expression through a starvation-like response, resulting in
the activation of many transcription factors and cofactors (including AMPK, SIRT1, and PGC-1α),
with consequent increase of mitochondrial biogenesis [51]. Additional exciting observations have
been reported in cellular models of PMD: KB alleviated mitochondrial dysfunction by restoring CI
assembly in cybrid model of MELAS [52], and reduced the mutation load of a heteroplasmic mtDNA
deletion in a cybrid cell line from a Kearns–Sayre syndrome patient [53], although the mechanisms of
such improvements still need to be deciphered. Similarly, a high-fat diet (HFD) protected fibroblasts
with CI deficiency and delayed the neurological phenotype of the Harlequin mouse [54]. A preclinical
trial in the Deletor mouse, overexpressing a mutant replicative helicase Twinkle, revealed slowing of
mitochondrial myopathy progression in mice treated with the KD [55]. BCS1L-mutated mice with
CIII deficiency and progressive hepatopathy fed with KD significantly attenuated liver disease [56].
However, other studies reported that KD could worsen the mitochondrial defect in the Mpv17 knockout
(ko) mouse, characterized by profound mtDNA depletion in the liver [57], in the Pank2 ko mouse
model [58] or in the astrocyte-specific ko mouse of the replicative mtDNA helicase Twinkle (TwKOastro),
a model of spongiotic mitochondrial encephalopathy with mtDNA depletion [59].
A modified ketogenic Atkins diet (mAD) was recently tested in patients with MM and progressive
external ophthalmoplegia with single or multiple deletions [60]. All patients developed progressive
muscle pain and rhabdomyolysis within two weeks; muscle ultrastructure analysis revealed selective
fiber damage [60]. These adverse events determined the interruption of the trial. Incredibly, a two-year
follow-up showed an increase in muscle strength, suggesting that, following the acute damage,
an injury-induced muscle repair by satellite cells—which do not carry deleted mtDNA molecules—was
stimulated. [60].
Other dietary approaches include the use of anaplerotic compounds to treat mitochondrial
fat oxidation disorders. An example is the odd-chain fatty acid triheptanoin, an anaplerotic
compound inducing a rapid increase of plasmatic C4- and C5-ketone bodies, the latter being a
precursor of propionyl-CoA, which is then converted into succinyl-CoA. Treatment with triheptanoin
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permanently abolished chronic cardiomyopathy, rhabdomyolysis, and muscle weakness in patients
with very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency [61].
In conclusion, in vitro and in vivo shreds of evidence suggest that dietary manipulation promotes
different responses in different tissues and cell types, highlighting the need for disease-specific
treatments based on their molecular pathophysiology knowledge.
3.3. Exposure to Hypoxia
Hypoxia response, a mechanism that helps cells adapting when oxygen is limited, was identified
in 2016 as a potent suppressor of mitochondrial dysfunction, and therefore proposed as a therapeutic
approach for mitochondrial diseases [62]. The authors identified the inhibition of the Von Hippel-Lindau
(VHL) factor as the most effective suppressor of the mitochondrial dysfunction. VHL factor is a
critical protein in cellular responses to oxygen availability, being required for the oxygen-dependent
proteolysis of α subunits of hypoxia-inducible factor-1 (HIF). VHL factor negatively regulates HIFs,
so downregulation of VHL activates the HIF transcriptional response, which induced the partial
shift of cellular bioenergetic reliance on mitochondrial OXPHOS [62]. Genetic or pharmacological
activation of the HIF pathway in cellular and zebrafish models, as well as chronic normobaric hypoxic
treatment in the murine Ndufs4 ko model of Leigh syndrome, prevented the development of the
disease. Hypoxia markedly improved lifespan (from 58 to 270 days), body weight, body temperature,
behavior, neuropathology, and disease biomarkers in Ndufs4 ko mouse, a model of severe infantile
Leigh syndrome; on the contrary, hyperoxia (55% O2) worsened all the parameters analyzed [62].
Alternate hypoxia/normoxia and moderate hypoxic conditions (17% O2) failed to improve the clinical
phenotype in Ndufs4 ko mice [63]. Confirmation of hypoxia’s therapeutic effects in additional models
of PMD and an in-depth explanation of the still unclear mechanistic details would open the possibility
of pharmacological treatment.
3.4. Strategies to Increase ATP Levels
The observation that combined oral administration of febuxostat—an inhibitor of xanthine
oxidoreductase (XOR) used to treat gout and hyperuricemia—and inosine elevated both hypoxanthine
and ATP levels in peripheral blood of healthy subjects [64], let Kamatani and colleagues hypothesize
that PMD patients may potentially benefit from such treatment.
Purine nucleoside phosphorylase catalyzes the conversion of inosine to hypoxanthine, that is
further processed to urate by XOR. The concomitant administration of febuxostat and inosine caused
a significant increase of the serum hypoxanthine levels. Hypoxanthine is then converted to IMP,
while elevated levels of ATP were observed [64,65]. Two PMD patients—one with homoplasmic
mutation (m.12192G>A) in the tRNA histidine (MT-TH) and mitochondrial cardiomyopathy, and the
other one with mitochondrial diabetes, carrying a heteroplasmic mutation in tRNA leucine 1
(MT-TL1)—received concurrent administrations of inosine and febuxostat. In the first case, the specific
marker of heart failure brain natriuretic peptide (BNP), was decreased by 31%, and in the second
case, the insulinogenic index increased 3.1 times, suggesting a favorable action of the treatment [65].
However, further studies are needed to confirm these findings.
3.5. Pharmacological Stimulation of Mitochondrial Biogenesis
Standard features of OXPHOS-related PMD include reduced ATP production and subsequent
energy failure. It has been well established that the onset of the clinical phenotype may appear
once the residual mitochondrial activity drops below a critical threshold [66]. In this context,
the activation of mitochondrial biogenesis could favor the cells residing in affected tissues to improve
the ‘mitochondrial energy units’ and ameliorate their energy metabolism. However, debates exist
regarding potential harmful consequences of increasing a mitochondrial mass composed mainly of
damaged mitochondria, variably characterized by enhanced ROS production and mtDNA damage [67].
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Nevertheless, several molecules pharmacologically targeting the mitochondrial biogenesis pathway
have been tested in the last decades.
The mitochondrial biogenesis is regulated by a complex signaling cascade requiring coordinated
transcription of several proteins encoded by the nuclear and mitochondrial genome. The mitochondrial
biogenesis pathway has been extensively investigated in brown adipose tissue and skeletal muscle.
The so-called master gene of mitochondrial biogenesis is the Peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α). This transcriptional coactivator physiologically acts as a
sensor of various external and internal stimuli (i.e., cold, exercise, nutritional status) to modulate the
mitochondrial mass to meet the energy requirements of the cells.
PGC-1α is a transcriptional coactivator of many transcription factors, including the nuclear
respiratory factors (NRF1 and NRF2) that control the transcript levels of OXPHOS-related genes [68],
the peroxisomal proliferator activator receptors (PPARs) that modulate fatty acid oxidation, as well as
estrogen-related receptor α (ERRα) [69], thyroid hormone receptor [70], that modulate thermogenesis
but also mitochondrial respiration [71]; transcription factor Yin-Yang 1 (YY1) implicated in respiratory
chain expression [72].
Genetic manipulations of preclinical models have confirmed the beneficial effects of the activation
of mitochondrial biogenesis pathway in MM. Transgenic mice overexpressing PGC-1α in skeletal muscle
had enhanced endurance performance and a fiber type conversion from type II to type I, with concurrent
activation of genes related to mitochondrial oxidative metabolism [73]. When PGC-1α is overexpressed
in the skeletal muscle of Surf1 ko [74] and other OXPHOS-deficient mice, including Acta-Cox15 ko and
Sco2 knockin-knockout (kiko) mice, a significant amelioration of the phenotypic and molecular aspects
of MM occurs (Bottani E, personal observations). On the contrary, selective depletion of PGC-1α leads
to a blunting of exercise-induced increase of MRC proteins in muscle [75,76].
PGC-1α gene expression is modulated by many stimuli, which share some common molecular
pathways despite the proven tissue-specificity of these mechanisms. Some of them include the
PKA/CREB pathway, the calmodulin-dependent protein kinase IV (CaMKIV) and calcineurin A (CnA)
pathway, and the NOS/cGMP/PGK pathway (for an extensive review, see [25]). Post-translational
modifications modulate PGC-1α activity; in particular, it is activated by phosphorylation triggered
by AMPK [77] or by deacetylation operated by the nuclear deacetylase Sirtuin 1 (SIRT1) [78].
The pharmacological modulation of both AMPK and SIRT1 activities is possible, and it has been
exploited to activate PGC-1α [25]. AMPK is a highly conserved sensor of intracellular adenosine
nucleotide levels activated when even modest decreases in ATP production result in relative increases
in AMP or ADP. In response, AMPK promotes catabolic pathways to generate more ATP and inhibits
anabolic pathways [79]. SIRT1 is an NAD+-dependent deacetylase that acts on various substrates
and is involved in an extensive assortment of physiological functions, comprising control of gene
expression, metabolism, and aging [80].
In the last decade, the PGC-1α signaling cascade has become an attractive therapeutic target to
manipulate mitochondrial function, and several drugs acting on the PGC-1α pathway have been tested
in preclinical models of PMD [74,81]. A schematic representation of PGC-1α pathway and modulating
factors are exemplified in Figure 2.
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Figure 2. Schematic representation of the pathways regulating mitochondrial biogenesis, dynamics, 
and mitophagy. External factors (exercise, caloric restriction, or drugs such as bezafibrate, 5-
aminoimidazole-4-carboxamide ribonucleoside (AICAR), resveratrol, or nicotinamide riboside 
(NR) upregulate the expression of PGC-1α, which in turn activates essential mitochondrial genes. 
Other drugs can act on NO pathway (PDE5 inhibitors as Sildenafil) or mitochondrial autophagy 
(Rapamycin). Blue arrows and squares indicate positive regulations, while red arrows and squares 
indicate negative regulations. 
3.5.1. 5-Aminoimidazole-4-Carboxamide Ribonucleoside (AICAR) 
The AMP analogue 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) has been used to 
induce PGC-1α-dependent mitochondriogenesis via the activation of the AMPK. We reported a 
robust induction of OXPHOS-related gene transcription with consequent increase of MRC complex 
activities in three preclinical models of COX deficiency, a Surf1 ko mouse, a Sco2 kiko mouse, and a 
muscle-specific Cox15 ko mouse [74]. The increase in the MRC activities was paralleled by a 
significant improvement in the kiko mouse’s motor performance, which has a mild MM, but not in 
Acta-Cox15 models. This difference is likely due to the severity of the Acta-Cox15 ko mouse model’s 
clinical phenotype, which could not be corrected despite a clear, although incomplete, rescue of the 
CIV activity. We also generated an Acta-Cox15 ko mouse model overexpressing PGC-1α in the 
skeletal muscle. This mouse (Acta-Cox15ko–PGC-1α) also showed improved motor performance 
compared to naive Acta-Cox15 ko littermates, but this effect was transient, and, at six months of age, 
both Acta-Cox15 ko and Acta-Cox15ko–PGC-1α displayed comparable motor performance, suggesting 
that the overexpression of PGC-1α in the skeletal muscle delayed, but did not arrest, the clinical 
course of the disease. Intriguingly, chronic (three months) AICAR administration improved CIV 
activity, rescued the motor phenotype, and delayed the onset of the myopathy in a mouse model of 
slowly progressing MM (Cox10-Mef2c-Cre), either in pre-symptomatic or post-symptomatic 
administration protocol [82]. However, the authors attributed the effects of AICAR in promoting the 
regeneration of muscle fibers rather than activation of mitochondrial biogenesis [82]. Interestingly, 
Golubitzky and co-workers identified AICAR as the most effective compound able to induce 
mitochondrial biogenesis without altering mitochondrial membrane potential (Δψ). AICAR also 
improved growth and ATP content while decreasing ROS production in CI deficient cells [83]. 
Nevertheless, the use of AICAR to treat CNS disease is limited by its low blood–brain barrier 
penetrance. Conversely, peripheral stimulation of AMPK and mitochondrial biogenesis may have 
some beneficial effects on MM. 
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3.5.1. 5-Aminoimidazole-4-Carboxamide Ribonucleoside (AICAR)
The AMP analogue 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) has been used
to induce PGC-1α-dependent mitochondriogenesis via the activation of the AMPK. We reported a
robust induction of OXPHOS-related gene transcription with consequent increase of MRC complex
activities in three preclinical models of COX deficiency, a Surf1 ko mouse, a Sco2 kiko mouse, and a
muscle-specific Cox15 ko mouse [74]. The increase in the MRC activities was paralleled by a significant
improvement in the kiko mouse’s motor performance, which has a mild MM, but not in Acta-Cox15
models. This difference is likely due to the severity of the Acta-Cox15 ko mouse model’s clinical
phenotype, which could not be corrected despite a clear, although incomplete, rescue of the CIV activity.
We also generated an Acta-Cox15 ko mouse model overexpressing PGC-1α in the skeletal muscle.
This mouse (Acta-Cox15ko–PGC-1α) also showed improved motor performance compared to naive
Acta-Cox15 ko littermates, but this effect was transient, and, at six months of age, both Acta-Cox15 ko and
Acta-Cox15ko–PGC-1α displayed comparable motor performance, suggesting that the overexpression of
PGC-1α in the skeletal muscle delayed, but did not arrest, the clinical course of the disease. Intriguingly,
chronic (three months) AICAR administration improved CIV activity, rescued the motor phenotype,
and delayed the onset of the myopathy in a mouse model of slowly progressing MM (Cox10-Mef2c-Cre),
either in pre-symptomatic or post-symptomatic administration protocol [82]. However, the authors
attributed the effects of AICAR in promoting the regeneration of muscle fibers rather than activation of
mitochondrial biogenesis [82]. Interestingly, Golubitzky and co-workers identified AICAR as the most
effective compound able to induce mitochondrial biogenesis without altering mitochondrial membrane
potential (∆ψ). AICAR also improved growth and ATP content while decreasing ROS production in CI
deficient cells [83].
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Nevertheless, the use of AICAR to treat CNS disease is limited by its low blood–brain barrier
penetrance. Conversely, peripheral stimulation of AMPK and mitochondrial biogenesis may have
some beneficial effects on MM.
3.5.2. Bezafibrate and Other PPAR Agonists
Bezafibrate is a fibrate drug, pan-agonist of the isoform alpha of the peroxisome
proliferator-activated receptor (PPARα), displaying anti-lipidemic activity. The mechanism of action
of fibric acid derivatives was elucidated in the 1990s, after identifying PPARs as targets of these
drugs. Upon activation, PPARs bind as obligate heterodimers with the retinoid X receptor (RXR) to
specific recognition sequences, called PPAR-response elements (PPRE), in the regulatory region of
target genes, leading to cis-activation of gene transcription. There are three isoforms of PPARs (α, β/δ,
and γ) characterized by different physiological functions and tissue specificity with high expression in
liver, heart, and skeletal muscle, where they promote upregulation of genes encoding enzymes of the
oxidation pathway [84,85] and fatty acid catabolism [86]. Initial experiments performed by Bastin et
al. revealed that bezafibrate administration exerted positive effects on MRC activities. In particular,
both control and MRC-deficient patients′ fibroblasts with some residual respiratory chain function
level upregulated the expression of several nuclear genes encoding subunits of CI, CIII, or CIV and
augmented the enzymatic activities of MRC complexes [87]. These effects were accompanied by the
increased expression of PGC-1α, NRF1/2, and Transcription Factor A, Mitochondrial (TFAM), the latter
controlling the transcription and replication of the mitochondrial genome. Encouraging results were
also obtained in SCO2 mutant fibroblasts, in which bezafibrate rescued the cytochrome c oxidase
(COX) defect [88]. Bezafibrate was also tested in fibroblasts of patients with a de novo heterozygous
c.1084G>A (p.G362S) DNM1L mutation [89]. In this case, Bezafibrate effectively normalized growth
on glucose-free medium, ATP production and oxygen consumption, and improved mitochondrial
morphology, although it caused a mild increase in ROS production at the same time [89].
However, controversial preclinical results in the activation of PGC-1α were obtained by using
bezafibrate [74,90]. Bezafibrate failed to induce mitochondrial biogenesis in vivo in two different mouse
models of COX deficiency [74]. Bezafibrate administration significantly delayed the accumulation
of COX-negative fibers and multiple mtDNA deletions in the Deletor mouse without inducing
mitochondrial biogenesis. On the contrary, mtDNA copy number, transcript, and MRC protein
amounts decreased in both Deletor and wild-type mice. Furthermore, bezafibrate induced severe
lipid oxidation effects, with hepatomegaly and loss of adipose tissue, through a mechanism involving
lipid mobilization by high hepatic expression of fibroblast growth factor 21 (FGF21) cytokine [90].
An 8-month bezafibrate treatment of the Mutator mouse—a premature aging model that harbors
a proofreading-deficient mtDNA polymerase γ—delayed hair loss and improved skin and spleen
aging-like phenotypes, without a generalized increase in mitochondrial markers, or improvements in
muscle function or lifespan [91].
Recently, the results of an open-label observational experimental medicine study of six patients
with MM caused by the m.3243A>G MTTL1 mutation were published [92]. The aim of this study
was to establish preliminary safety and efficacy evidence of bezafibrate on mitochondrial metabolism.
No clinically adverse events were reported after the administration of 600–1200 mg bezafibrate daily
for 12 weeks to the enrolled patients [92]. A reduction in the number of COX-immunodeficient muscle
fibers and improved cardiac function were observed in treated patients. Curiously, some biomarkers,
comprising the level of m.3243A>G heteroplasmy in urinary sediments or the exercise physiology,
were extremely erratic, explaining why these do not always correlate with clinical severity. Moreover,
the known serological biomarkers for PMD, FGF-21, and growth and differentiation factor 15 (GDF-15),
were significantly elevated and paralleled by a strong imbalance in amino acid and fatty acid
metabolism [92]. This alteration of mitochondrial disease patients’ metabolomic signature following
bezafibrate administration suggests being cautious with eventually possible adverse events in
long-term treatment.
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Thiazolidinediones are a class of heterocyclic compounds used to treat type 2 diabetes mellitus
that display a high affinity for the PPARγ receptor. Once activated, the PPARγ binds to DNA in
conjunction with the RXR receptor, and this heterodimer interacts with transcriptional coactivators,
including PGC-1α [93]. Several lines of evidence support the mitochondriogenic effects of
thiazolidinediones compounds, both in in vitro and in vivo models [94–96]. Interestingly, Rosiglitazone
(a member of this family) simulated mitochondrial biogenesis in mouse brain through an apolipoprotein
(Apo) E isozyme-independent manner. Rosiglitazone induced both mtDNA and estrogen-stimulated
related receptor alpha (ESRRA) mRNA, a key regulator of mitochondrial biogenesis. PPARγ agonism
induced neuronal mitochondrial biogenesis and glucose utilization, leading to progressed cellular
function [97]. However, studies on preclinical models of PMD are lacking.
3.5.3. Modulating NAD+ Pool
Another strategy to stimulate mitochondrial biogenesis is based on pharmacological activation of
SIRT1, a nuclear deacetylase that utilizes the NAD+ moiety to deacetylate acetyl-lysine residues of
proteins. Downstream targets of SIRT1 are the Forkhead box O (FOXO), PGC-1α, the myocyte-specific
enhancer factor 2 (MEF2), and the tumor suppressor p53 [98], which are involved in the
transcriptional regulation of mitochondrial function. As SIRT1 activity is directly regulated by
NAD+ availability, NAD+’s intracellular regulation may represent a strategy to promote SIRT1 activity
and its downstream cascade. Various approaches can increase intracellular NAD+ concentrations,
including (I) supplementation with NAD+ precursor [99,100]; (II) pharmacological inhibition of poly
(ADP) ribosyl polymerase 1 (Parp1), an NAD+ consumer, and SIRT1 competitor [101,102]; or (III) by
inhibition of aminocarboxymuconate semialdehyde decarboxylase [103], which results in increased de
novo synthesis of NAD+ from tryptophan.
Vitamin B3 is a NAD+ precursor and exists in several forms: nicotinic acid (niacin), nicotinamide
(NAM), and nicotinamide riboside (NR) [100,104,105]. Supplementation with NR and reduction of
NAD+ consumption by inhibiting the Parp enzymes were tested in Sco2 kiko mice leading to activation
of SIRT1, and induction of OXPHOS genes via the PGC-1α axis, resulting in clinical improvement of the
motor performance of treated mice up to normal values [81]. Similarly, NR’s administration activated
mitochondrial biogenesis, improved mitochondrial ultrastructure, prevented the generation of multiple
mtDNA rearrangements, and delayed the MM in the Deletor mouse model [106]. It was also reported that
NR administration improved mitochondrial function in iPSC-derived neurons from Parkinson’s Disease
(PD) patients and rescued neuronal loss and motor deficits in GBA-PD Drosophila melanogaster [107].
Nicotinamide mononucleotide (NMN), another NAD+ precursor, significantly extended the lifespan
of the Ndufs4 ko mice by approximately 2-fold [108]. NMN also attenuated NAD+ redox imbalance,
protein hyperacetylation, and suppressed lactate levels in the skeletal muscle, while brain was not
responsive [108].
A recent paper from Katsyuba and co-workers demonstrated that cellular NAD+ levels are also
controlled by α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD), the enzyme
that limits the proportion of ACMS able to undergo spontaneous cyclization in the de novo NAD+
synthesis pathway, through a conserved evolutionary mechanism from C. elegans to the mouse [103].
RNAi of ACMDS led to increasing mitochondrial mass and respiration, and ultimately lifespan of
worms through the activation of the mitochondrial stress response. Moreover, ACMSD inhibitors
effectively modulate NAD+ levels and mitochondrial function in vitro and in vivo, particularly in
mouse models of liver and kidney injury [103].
A systemic NAD+ deficiency has recently been reported in patients with an adult-onset type of MM.
An elevated dose of niacin (to 750–1000 mg/day) was administered in 416 patients and their matched
controls, for 10 or 4 months, respectively (ClinicalTrials.gov identifier NCT03973203). Blood NAD+
grew to 8-fold in all participants, and the patients’ muscular NAD+ achieved the control level.
Mitochondrial mass and muscle strength increased in all patients; furthermore, muscle metabolism
normalized, and liver fat dropped by as much as 50% in patients. Lessened concentration of hemoglobin
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and erythrocytes and increased muscle glycogen have been identified as potential adverse reactions
which need focus and follow-up. Similar increases in circulating NAD+ were reported with NR
treatment in healthy subjects [109]. These data point to a possible interference of NAD+ precursors
with erythropoiesis and/or iron metabolism, which require an appropriate supervising in the context
of B3 supplementation [105]. However, these data suggest niacin as a good candidate to treat MM with
NAD+ deficiency, whereas possible curative effects on other PMD are still unclear.
3.5.4. I-BET 525762A
Through a high-throughput chemical screen, Barrow and co-workers identified I-BET 525762A,
a bromodomain inhibitor, as a top hit that augments COX5a protein levels in CI-mutant cybrid cells.
In parallel, bromodomain-containing protein 4 (BRD4), a target of I-BET 525762A, was identified
using a genome-wide CRISPR screening to search for genes whose loss of function rescues the death
of CI-impaired cybrids. Furthermore, I-BET525762A administration, or loss-of-Brd4, remodeled the
mitochondrial proteome and increased the levels and activity of OXPHOS protein complexes,
rescuing the CI defects and cell death [110]. BRD4 is a chromatin-bound transcriptional regulator linked
to the expression of genes associated with different biological processes, including tumor progression
or inflammation [111]. These findings suggest that these programs integrate with mitochondrial
energetics and metabolic control, although the precise mechanism(s) needs still to be deciphered.
3.5.5. Polyphenols and Other Pharmacognostic Products
Resveratrol (2,3,4′-trihydroxystilbene) is a polyphenol that received attention for a range of potentially
beneficial effects, including mitochondrial function improvement, anti-inflammatory properties,
and protection against metabolic diseases and neuronal dysfunction. In 2003, resveratrol (RSV)
was identified as the most potent SIRT1 activator molecule in a drug screening [112]. Since then,
many studies have pointed to the ability of RSV to upregulate the Sirt1-mediated mitochondrial
biogenesis and the functions of other key players as AMPK and PGC-1α. Although the effects of RSV
in inducing mitochondrial biogenesis are well established and reproducible [113,114], concerns exist
on the molecular mechanism(s) of action. Some authors reported that RSV acts primarily on AMPK
activation [115,116], and that the activation of SIRT1 by RSV is an artifact [117–119]. In line with
this hypothesis, Jee-Hyun Um et al. showed that RSV was unable to exert its pharmacological
effects in AMPK deficient mice, proving that AMPK is a crucial target of RSV [120]. Other authors
instead reported that RSV might first activate SIRT1 in vivo, leading to AMPK activation [121,122],
and deacetylation of PGC-1α [114]. However, different RSV dosages preferentially activate SIRT1
or AMPK in vivo, further increasing the complexity of these pathways [113]. Besides the molecular
mechanisms, studies based on preclinical neurodegenerative disease models reported positive effects
of RSV in improving mitochondrial function and neurological symptoms [123,124]. More recently,
the effects of RSV administration on mitochondrial respiration of skin fibroblasts from PMD-patients
have been reviewed [125]. It appeared clear that responses to RSV are not uniform but highly patient- or
mutation-dependent. Further studies on proper cellular models are needed to evaluate the effects of RSV
on PMD.
Quercetin is a potent antioxidant flavonoid, more specifically a flavonol, with a reported ability
to activate SIRT1 and PGC-1α and increases mtDNA and cytochrome c content in skeletal muscle
and brain [126,127]. The use of quercetin for the treatment of neurodegenerative disorders with
mitochondrial involvement has been exploited in preclinical models of Alzheimer’s Disease [128] and
Parkinson’s disease [129].
Hydroxytyrosol (HT) is a polyphenol which activated PGC-1α through SIRT1 de-acetylation and
induced mitochondrial biogenesis in vitro [130] and in skeletal muscle in vivo [131]. Furthermore,
HT exerted dose-dependent effects on SC assembly in exercised animals through enhancing
mitochondrial function [132]. Prolonged HT administration significantly activated AMPK, SIRT1,
and PGC-1α, and increased the MRC complexes’ levels in the brain of db/db mice. Likewise,
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targets of the antioxidative transcription factor nuclear factor erythroid 2 related factor 2 (NRF2),
including p62 (sequestosome-1), heme oxygenase 1 (HO-1), and superoxide dismutase 1 and 2
increased, and protein oxidation significantly decreased upon treatment [133]. Recently, by using three
different C. elegans models of PD, it was shown that HT enhanced locomotion in worms suffering from
α-synuclein-expression in muscles or rotenone exposure, reduced α-synuclein accumulation in muscle
cells, and prevent neurodegeneration in α-synuclein-containing dopaminergic neurons [134].
Curcumin—a dietary polyphenol derived from turmeric—also stimulated different mitochondrial
biogenesis markers in vivo when administered to the senescence-accelerated mouse-prone 8 (SAMP8)
strain. In particular, curcumin upregulated PGC-1α protein expression in the brain, improving MMP
and ATP levels and restoring mitochondrial fusion [135]. In another study, curcumin dietary
supplementation increased the expression of TFAM and PGC-1α, and ATP levels in mouse brains [136].
Curcumin also showed antioxidant effects in patients affected by β-Thalassemia [137,138]. Therefore,
curcumin was proposed to treat LHON patients in phase 3 clinical trial (ClinicalTrials.gov identifier
NCT00528151). Seventy patients with 11,778 LHON mutation were randomly treated with oral
curcumin (500 mg/day) or placebo for one year. The visual acuity, computerized visual field,
electrophysiologic parameters, and oxidative stress enzymes in plasma were compared before and after
treatment at 3-, 6-, and 12-month intervals. Although the study was completed in 2007, results have
not been published to date.
Despite the wide choice of molecules with a potential effect on mitochondrial biogenesis, more effort
is needed to clarify which drug is most effective in patients affected by PMD. Bezafibrate gave highly
variable results; AICAR presents several limitations for chronic use [139,140]; furthermore, the potential
mutagenic effects of PARP inhibitors are still to be thoroughly evaluated, although data collected in
patients treated with Olaparib (AZD-2281) suggest low mutational toxicity [141]. On the contrary,
the possibility of translating into clinical practice supplementation with NAD+ precursors seems to be
more realistic, based on the high tolerability and substantial lack of adverse effects [142–144].
3.6. Pharmacological Modulation of the NO/cGMP/PKG Pathway
Nitric oxide (NO) is an intra- and extra-cellular gaseous second messenger that acts on
various signaling pathways in target cells and orchestrates a plethora of physiological processes,
including neuronal signaling, modulation of ion channels, immune response, inflammation,
and cardiovascular homeostasis, among others. NO is catalytically produced from L-arginine and
L-citrulline—the latter is converted to L-arginine via argininosuccinate synthase and argininosuccinate
lyase—by the three isoforms of the enzyme nitric oxide synthase (NOS): the neuronal NOS (nNOS,
or NOS1), inducible NOS (iNOS or NOS2), and endothelial NOS (eNOS or NOS3). Since mitochondria
also produce NO, the existence of a putative mitochondrial NOS (mtNOS) is feasible, yet still
controversial [145–147]. The enzymatic reaction generating NO involves the transfer of electrons
from NADPH, via the flavins in the C-terminal reductase domain, to the heme in the N-terminal
oxidase domain of NOS, where the substrate L-arginine is oxidized to L-citrulline and NO [148].
Stimulation of NOS leads to the generation and release of NO, which causes the activation of soluble
guanylate cyclase (sGC) and cGMP production. The biological effects of cGMP are mediated by
three major groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated ion
channels, and phosphodiesterases (PDEs) [149]. Once activated by cGMP, PKGs initiates a cascade of
phosphorylation events on various target proteins, resulting in modification of physiological processes,
including calcium homeostasis, smooth muscle contraction, and cardiac function [149]. cGMP-gated
channels are non-selective ion channels that function in response to cGMP binding and have important
signal transduction roles in retinal photoreceptors and olfactory receptor neurons [150]. However,
it should be noted that, other than cGMP-gated channels, many other ion channels are indirectly
regulated by cGMP through PKG-consensus motifs on their sequence [151,152]. Lastly, the cGMP
level is determined by the balance between sGC and PDEs activities, the latter breaking down cGMP
molecules [149]. Notably, it has been reported that the NOS/NO/sGC/cGMP signaling upregulates
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PGC-1α [153] in diverse cell types, including neurons [154,155]. The mechanisms by which cGMP
activate PGC-1αmay involve the PKG-driven modulation of the CREB signaling pathway, which has
been recently reviewed elsewhere [156].
NO deficiency occurs in PMD and may be due to multiple factors, although not fully elucidated.
The first hypothesis points to a generalized impairment of endothelial function, as observed in PMD [157].
Flow-mediated vasodilation (FMD), which is a function of NO synthesized by endothelial cells in response
to reperfusion, is impaired in individuals with MM, MELAS, MERRF, MIDD (maternally inherited
diabetes and deafness), and CPEO [158]. As often reported, abnormal mitochondrial proliferation may
cause NO sequestration by CI and CIV binding [159]. Finally, reduced levels of NO precursors [160–162]
and of sarcoplasmic NOS activity in COX-negative fibers from patients with PEO, MM, and MELAS
syndrome were reported [163]. Beyond the cause(s), NO depletion may play a significant role in the
onset of several observed complications, including stroke-like episodes, myopathy, diabetes, and lactic
acidosis [164]. Subjects with MELAS syndrome have lower concentrations of NO metabolites (nitrite and
nitrate) during stroke-like episodes [165] and low L-citrulline levels, suggesting that MELAS strokes may
be caused by unstable NO homeostasis that leads to vascular endothelial dysfunction [161].
3.6.1. L-Arginine and L-Citrulline
As L-arginine and L-citrulline are NO precursors, their supplementation was proposed to treat
NO deficiency-related manifestations of PMD [161,166,167]. L-Arginine supplementation increased
the NO production rate [164] and improved FMD in MELAS patients [162]. An open-label trial
showed that intravenous L-arginine administration to MELAS patients during stroke-like episodes
led to an improvement in the clinical symptoms associated with these episodes, and oral L-arginine
supplementation at the interictal phase decreased their frequency and severity [165]. A series
of open-label studies confirmed these findings in MELAS patients with the common m.3243A>G
mutation [162,168]. Interestingly, the NO synthesis rate effectively increased upon L-citrulline
supplementation, rather than L-arginine, indicating that L-citrulline is a more powerful NO precursor
than L-arginine [164,169]. Moreover, L-arginine and L-citrulline administration reduced plasmatic
alanine and lactate concentrations, suggesting that such supplementation may improve lactic acidemia
in MELAS syndrome by improving NO-mediated perfusion and oxygen delivery in all microvasculature
compartment [167]. So, the L-citrulline and L-arginine supplementation may also be extended to treat
other clinical features of PMD, e.g., lactic acidosis, muscle weakness, exercise intolerance, and diabetes.
As such, a randomized crossover study (ClinicalTrials.gov identifier NCT02809170 was performed
to evaluate the impact of L-citrulline and L-arginine supplementation on endothelial dysfunction in
pediatric PMD patients. The primary outcomes were the changes in reactive hyperemic index, which
reflects endothelial function, but results are not yet available. Currently, a Phase-1 clinical trial is
recruiting patients to establish dose and safety of L-citrulline treatment of NO deficiency in MELAS
(ClinicalTrials.gov identifier NCT03952234). Placebo-controlled randomized clinical trials are necessary
before L-arginine and L-citrulline can be definitively recommended to ameliorate or treat stroke-like
episodes in MELAS and other PMD.
3.6.2. Natriuretic Peptides and Cyclic Guanosine Monophosphate
Natriuretic peptides (NPs) induce natriuresis (i.e., the excretion of sodium by the kidney).
NPs regulate vascular tone via GC, cGMP, and PKG [170]. The polypeptide hormones Atrial natriuretic
peptide (ANP) and brain natriuretic peptide (BNP) regulate the vascular tone and natriuresis. ANP and
BNP stimulate the production of cGMP via a selective binding to their receptors, the natriuretic
peptide receptors A and B (NPRA/GC-A and NPRB/GC-B, respectively) which so activate their
intracellular guanylate cyclase domains [170]. Transgenic mice overexpressing BNP or PKG increased
the mitochondrial muscle content and fat oxidation through upregulation of PGC-1α and PPARδ,
preventing obesity and glucose intolerance; moreover, treatment of myotubes with ANP and BNP
stimulates mitochondrial biogenesis and mitochondrial respiration [171]. Exercise induced expression
Pharmaceutics 2020, 12, 1083 14 of 63
of NPRA/GC-A and was correlated with the expression of PGC-1α-dependent genes in muscle [172].
Whitaker et al. showed that phosphodiesterase type-3 (PDE3) inhibitors cilostamide and trequinsin
increased PGC-1α levels, mRNA expression of mitochondrial genes, and mtDNA copy number both
in renal proximal tubular cells and in the renal cortex [173]. However, these compounds have not
been tested on PMD models yet, and therefore, future studies are necessary to exploit their potential
therapeutic effects.
3.6.3. PDE5 Inhibitors
Sildenafil is the first specific phosphodiesterase type-5 (PDE5) inhibitor (PDE5i) marketed to
treat erectile dysfunction. PDE5 is expressed in many tissues where it hydrolyzes intracellular
cGMP; thus, PDE5i potentiates the endogenous increase of cGMP by inhibiting its breakdown [174].
Sildenafil restored mitochondrial biogenesis and favored renal recovery in mice after folic acid-induced
acute kidney injury [173]. A recent study showed that sildenafil treatment induced mitochondrial
biogenesis, increased UCP-1 expression, and promoted subcutaneous white adipose tissue browning
in healthy mice [175]. Moreover, PDE5is have emerged from drug screening on MILS-neuronal
progenitor cells (NPCs) as the most effective drug to ameliorate mitochondrial function. NPCs derived
from patients carrying a deleterious homoplasmic mutation (m.9185T>C) in the mitochondrial gene
MT-ATP6 showed defective ATP production and abnormally high mitochondrial membrane potential
(MMP), with altered calcium homeostasis [176].
Avanafil, a PDE5i, rescued the calcium defect in patient NPCs and differentiated neurons [176].
However, the NO pathway was not evaluated in this study; instead, a possible link with the activation
of Ca2+-activated potassium channels mediated by cGMP was speculated [176]. Nevertheless,
the beneficial effects of PDE5i to treat PMD are still poorly understood, since preclinical studies [177,178]
and case reports [179] gave controversial results; further investigations on the mechanisms need to
be implemented.
3.7. Antioxidants
Reactive oxygen species (ROS) are unstable molecules containing oxygen that can quickly react with
other molecules within cells. They are generated primarily as by-products of the enzymatic activities of
the mitochondrial electron transport chain. ROS molecules comprise superoxide, hydrogen peroxide,
hydroxyl radical, and hydroxyl ion. Hydrogen peroxide is not as reactive as the hydroxyl radical,
yet the latter is readily generated by the former in the presence of Fe3+, through the so-called Fenton
reaction. Mitochondria are the primary site of ROS production within the cell. In physiological
conditions, ROS act as signaling molecules through a tightly regulated process in cell proliferation [180],
development, immunity, apoptosis, among others [181], while are scavenged by different antioxidant
enzymes that include various isoforms of glutathione peroxidase (GP), superoxide dismutase (SOD),
and peroxiredoxin (Prx) [182]. In pathological conditions due to mutations in genes involved in the
OXPHOS system, the inefficient transfer of electrons among the four respiratory chain complexes
causes an accumulation of electrons that react with molecular oxygen to form superoxide anions
(O2−) [183], superoxide dismutase enzymes then convert that to H2O2, which can be further reduced
to hydroxyl radical (OH−), the most potent oxidizing agent among the ROS [183]. Therefore,
ROS generation is enhanced, leading to ROS-mediated, irreversible cellular damage, including lipid
peroxidation, DNA modifications, and cell death [182]. Moreover, ROS further damage MRC complexes,
including NADH dehydrogenase, cytochrome c oxidase, and ATP synthase, and alter mitochondrial
membrane permeability and structure, resulting in a complete shutdown of mitochondrial energy
production (for a detailed review, see Guo et al. [184]).
Therefore, using antioxidant drugs in mitochondrial disease treatment is mainly related to the
mitigation of such toxic effects. Antioxidant drugs do not target any specific biochemical pathways
directly but help improve cellular energy metabolism regulation. Due to their non-specific mechanism,
these drugs can be used in various PMD with an accumulation of mitochondrial ROS. Several antioxidant
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drugs have variable degrees of efficacy in terms of longevity and mitigation of oxidative stress in
preclinical models of CI defects, pointing at the importance of such treatments in the therapy of
PMD [185]. The currently used antioxidant drugs, their clinical uses in MRC diseases, and clinical
trials results are discussed below.
3.7.1. Glutathione
Glutathione (GSH; γ-glutamyl-cysteinyl-glycine) is a tripeptide that contains an unusual γ-amide
bond; it is a critical intracellular antioxidant agent that is the substrate of several peroxidases, helping to
destroy peroxides generated by oxidases. Reduced blood GSH and redox imbalance have been reported
in various PMD-patients [186,187]; therefore, supplementation of glutathione precursors may counteract
ROS-driven damage. Cysteine donors have received increasing attention as cysteine is the rate-limiting
substrate for glutathione biogenesis. However, a 30-day, double-blind, cross-over study providing an
oral supplement with a glutathione precursor significantly reduced the oxidative stress biomarkers yet
did not modify lactate concentration, clinical scale, or quality of life of the individuals [188]. Beyond its
role of GSH precursor, cysteine is required for the 2-thiomodification of mitochondrial tRNAs, which is
therefore useful for treating mtDNA mutations affecting mitochondrial transfer tRNA. Supplementation
with cysteine, but not N-acetyl-cysteine, partially rescued the mitochondrial translation defect in
fibroblasts of patients carrying the m.3243A>G and m.8344A>G mutations, suggesting a possible
benefit in a subgroup of patients with impaired mitochondrial translation [189].
3.7.2. Cysteamine
Cysteamine is an amino thiol that is synthesized in mammals, including humans, through the
breakdown of Coenzyme A. Cysteamine is an FDA-approved drug for the treatment of cystinosis.
This lysosomal storage disease results from defects in the lysosomal cystine transporter (cystinosis),
leading to a pathological accumulation of cystine-crystals in lysosomes [190]. Cysteamine exerts its
function by entering into the lysosomes where it converts cystine into cysteine and cysteine-cysteamine
disulfide, both of which can exit the lysosome [191]. Therefore, cysteamine increases the glutathione
precursor cysteine availability, raising the possibility of its repositioning as a drug for PMD. A recent
study evaluated cysteamine bitartrate’s therapeutic potential in three different models of mitochondrial
disorders: C. elegans model of CI defect, FBXL4 mutant human fibroblast, and zebrafish models of
pharmacologically-induced CI and CIV defects [192]. Although a therapeutic potential has been
observed, no evident modulation of total glutathione levels was reported, raising concerns about its
application in MRC diseases [192].
The microsphere formulation of Cysteamine bitartrate delayed-release (RP103) [193] has been
used in a clinical trial. An open-label, dose-escalating study assessing safety, tolerability, efficacy,
pharmacokinetics, and pharmacodynamics of RP103 in children affected by inherited PMD was
completed in November 2017. RP103 was administered up to 1.3 g/m2/day in two divided doses,
every 12 h, for up to 6 months. The primary outcome measured focused on changes from baseline in
Newcastle Paediatric Mitochondrial Disease Scale Score (NPMDS). Secondary outcomes focused on
the measurement of glutathione, lactate, glutathione disulfide, lactate, and evaluation of myopathy by
6 Minute Walk Test. The data analysis is ongoing (ClinicalTrials.gov Identifier NCT02023866).
3.7.3. N-Acetylcysteine
N-acetylcysteine (NAC) also increases glutathione synthesis by increasing cysteine availability,
which is, as mentioned above, a rate-limiting substrate for GSH biosynthesis [194]. NAC has
been successfully used in a mouse model of ethylmalonic encephalopathy [195]. Ethylmalonic
encephalopathy is a severe, fatal disorder caused by mutations in the ETHE1 gene which encodes
a mitochondrial sulfur dioxygenase necessary for the detoxification of sulfide [196]; therefore,
mutations in ETHE1 gene lead to the accumulation of hydrogen sulfide, that is a potent inhibitor of
cytochrome c oxidase [197]. Since the supplementation of NAC replenishes the intracellular pool of
Pharmaceutics 2020, 12, 1083 16 of 63
reduced glutathione, the sulfide is effectively buffered. NAC supplementation is currently used in
patients with ethylmalonic encephalopathy [198–200], with encouraging results.
3.7.4. Lipoic Acid
Lipoic acid (also called α-lipoic acid) is an essential cofactor covalently bound to several
mitochondrial multi-enzymatic complexes, including the ketoglutarate dehydrogenase and pyruvate
dehydrogenase [201], involved in energy metabolism. Lipoic acid is also a potent ROS scavenger [202]
and antioxidant regenerator in vitro (mainly of CoQ10, vitamin C, and glutathione) [203]. However,
any increase in radical scavenging activity in vivo is unlikely to be sustained [204], due to the rapid
elimination of its free form from cells. Nevertheless, lipoic acid is often administered with other
antioxidants to PMD patients [205]. A randomized, double-blind, placebo-controlled, crossover study
with 16 patients with mitochondrial diseases demonstrated that the supplementation of lipoic acid
combined with creatine monohydrate and CoQ10 was able to decrease the levels of oxidative stress
markers measured in urine, with parallel amelioration of clinical symptoms [206].
3.7.5. Vitamin C
Limited cases are documenting some improvements with Vitamin C administration, alone or in
combination with other drugs. Progressive spasticity in a patient with familial spastic paraparesis
and multiple MRC defects was arrested by combined treatment with CoQ10, carnitine, vitamin C,
and K [207]. Other patients with CIII defect showed mild recovery of some clinical symptoms by
combining vitamin C and vitamin K administration [208,209]. However, other patients failed to
respond to similar treatment [210].
3.7.6. Vitamin E
The vitamin E-derivative Trolox has been successfully used as ROS scavenger in fibroblasts
from patients with CI defect, ameliorating the enzymatic activity’s deficit, supporting evidence that
CI expression may be controlled by the cell’s oxidative balance [211]. Moreover, chronic Trolox
administration in patients’ fibroblasts with CI defects did restore mitochondrial membrane potential
and normalized ER Ca2+ uptake without affecting control cell lines [212].
3.7.7. Coenzyme Q10
Coenzyme Q10 (CoQ10, or ubiquinone) is an endogenous, small lipophilic redox-active
benzoquinone derivative with an isoprenoid side chain synthesized in every cell apart of erythrocytes.
CoQ10 is an essential mobile electron carrier, which transfers electrons to mitochondrial respiratory
chain CIII from CI and II and the oxidation of fatty acids and branched-chain amino acids. Moreover,
CoQ10, in its reduced form (ubiquinol), is an effective lipophilic antioxidant that protects cellular
membranes from ROS-mediated oxidation and maintains the vitamin E and vitamin C in their
reduced form [213]. CoQ10 supplementation may be expected to benefit patients with disorders of
the mitochondrial respiratory chain by several mechanisms that are not mutually exclusive. First,
it would be useful in patients affected by primary or secondary CoQ10 deficiencies, in which there is a
pathological reduction of CoQ10 due to mutations in genes directly or indirectly involved in the CoQ10
biosynthetic pathway, that are, therefore, clinically heterogeneous [214,215]. Second, for the electron
carrier properties mentioned above, CoQ10 could facilitate electron transport by circumventing a block
in the electron transport chain, similar to what has been demonstrated for CIII defect treated with high
doses of vitamin C and vitamin K3 [216]. Third, because of its antioxidant properties, CoQ10 may
accept electrons from disrupted electron transport and reduce ROS formation risk that might cause
various cellular damage [217,218]. This is the most general mechanism, potentially applicable to any
defect of electron transport [219]. CoQ10 is the most common supplement used in PMD patients
because it is well tolerated and lacks any chronic side effects. Recent work also provided evidence
that CoQ10 may act as an enhancer of Parkin-mediated mitophagy flux in trans-mitochondrial cybrids,
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fibroblasts, and mutant-induced neurons derived from a MERRF patient, with partial improvement of
the cellular bioenergetics and pathophysiology [220].
The first paper reporting beneficial effects of CoQ10 administration in vivo was published in 1986
and described the effects in five patients with Kearns–Sayre syndrome (KSS). The administration of
CoQ10 as monotherapy improved abnormal metabolism of pyruvate, as seen by pyruvate/lactate ratio
in the cerebrospinal fluid, and NADH oxidation in skeletal muscle, with concomitant amelioration
of neurologic symptoms [221]. Since then, many studies have assessed the therapeutic potential of
CoQ10 administration in patients with mitochondrial respiratory chain disorders. One-year treatment
with 120 mg/day of CoQ10 in seven patients with KSS and other mitochondrial myopathies with CPEO
demonstrated a progressive reduction of serum lactate and pyruvate levels following standard muscle
exercise and generally improved neurological functions. Consistent findings on the normalization
of pyruvate and lactate levels after exercise have been reported in many clinical studies [222–224].
A patient with mitochondrial encephalomyopathy with COX deficiency was treated for two years with
a high dose of CoQ10 with beneficial effects on pyruvate metabolism and neurological function [225].
Another chronic, 2-year treatment with CoQ10 in oral doses of 150–100 mg/day in a patient with KSS
syndrome and significantly reduced levels of CoQ10 in serum and skeletal muscle biopsy resulted
in a marked physical and behavioral improvement. Tremor and ataxia disappeared, but external
ophthalmoplegia, retinal degeneration, and cardiac function were unchanged [226]. Treatment with
CoQ10 improves mitochondrial respiration in skeletal muscle and brain. One study reported that
6 months of treatment with CoQ10 (150 mg/day) in 10 patients with mitochondrial cytopathies
remarkably improved all brain MRS-measurable variables and muscle rate mitochondrial respiration
in all subjects [227]. Supplementation of CoQ10 and succinate resulted in clinical improvement of
the respiratory function of a patient with Kearns-Sayre and chronic external ophthalmoplegia plus
(KS/CEOP). In this case, the patient had virtually no CI activity as a consequence of 4.9 kDa mtDNA
deletion; thus, the rationale of the combined treatment was a bypass of the CI defect by feeding the
electron transport chain with succinate, plus the electron shuttle CoQ10. A direct association between
treatment regime and improved clinical status of the patient was documented [228].
In contrast, other studies failed to demonstrate any significant, reproducible, objective clinical
improvement following CoQ10 administration in a variety of PMD patients [229]. However, the authors
reported only a short treatment (2 months). CoQ10 treatment also failed to improve ptosis and
CPEO [230]. Clinical trials also reported little if no benefit in patients with PMD: a study that
enrolled 12 patients with different OXPHOS defects failed to demonstrate any clinical improvement
upon CoQ10 treatment, regardless of its ability to promote ATP synthetic capacity in peripheral
lymphocytes [231]. A randomized, double-blind, cross-over trial was performed in 30 patients with
mitochondrial disorders, who received 1200 mg/day CoQ10 for 60 days. Although the treatment
benefited from aerobic capacity and post-exercise lactate, it did not affect other clinically relevant
variables [232]. In a multicenter study, eight patients with different PMD and documented CoQ10
defect received 300 mg/day of ubiquinone for 12 months; only subjective improvements on exercise
intolerance, fatigue, and stiffness were reported, without any other significant amelioration of other
clinical signs [233]. In the same study, CoQ10 was also administered to 15 patients with myopathy
and normal CoQ10 levels in muscle. Only one patient, presenting with encephalomyopathy and
an unknown genetic defect, reported subjective improvement of fatigue [233]. A phase 3 trial of
CoQ10 (ClinicalTrials.gov identifier: NCT00432744) in children with PMD has been designed and
implemented; the future outcomes will highlight any therapeutic effects [234].
3.7.8. Idebenone
Since the CoQ10 is lipophilic, water insoluble, and poorly absorbed in the gut, novel formulations
with improved bioavailability have been developed. Idebenone is an organic molecule of the quinone
family, with hydrophilic and redox-active properties, that increases the ATP production, reduces free
radicals, inhibits lipid peroxidation, and consequently protects the lipid membranes and mitochondria
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from oxidative damage [235]. Its pharmacokinetic profile is more favorable than that of its analogue
CoQ10 [236]. In rats and dogs, the idebenone plasma plateau is reached after 15 min from the
administration, with a variable decline of half-life; moreover, idebenone is quickly and homogeneously
distributed in the body, but the brain tends to lose its drug content very rapidly [235].
Idebenone is the only EU approved drug for the treatment of LHON. Treatment of fibroblasts from
LHON patients with idebenone gave rise to increased CI activity, but yielded contradictory results
on mitochondrial respiration, leading to impairment in some cases and stimulation in others [237].
Another study on LHON fibroblasts displayed metabolic alterations that were reversed by idebenone
treatments, together with a significant rescue of CI activity [238]. The pharmacological effects of
idebenone in retinal ganglion cells (RGC, which are inactive but viable in LHON patients) and in
a mouse model of LHON were protective on retinal toxicity and visual impairment induced by CI
dysfunction [239]. The first complete randomized, placebo-controlled, double-blind clinical trial in
LHON (Rescue of Hereditary Optic Disease Outpatient Study “RHODOS”, ClinicalTrials.gov identifier:
NCT00747487) was conducted in 85 LHON patients with m.3460G>A, m.11778G>A, and m.14484T>C
mutations. This study demonstrated the safety and well tolerability of idebenone (900 mg/day
for 24 weeks) and reported amelioration of the visual outcome in a subgroup of patients [240].
Another randomized, double-blind placebo-controlled intervention study investigated the red–green
(protan) and blue–yellow (tritan) color contrast sensitivity in 39 LHON patients, demonstrating
significant protection from loss of color vision in subjects receiving idebenone for 6 months [241].
A clinical trial consisting of a single visit follow-up observational study in a subset of patients enrolled
in the RHODOS study (RHODOS-OFU, ClinicalTrials.gov identifier: NCT01421381) demonstrated
that the beneficial effect of idebenone treatment persisted despite discontinuation of therapy [242].
Additional studies are required to confirm these initial observations.
While use for LHON patients is well described, the exact mechanism is still undeciphered.
However, beneficial effect of idebenone administration was described in an old adolescent patient
suffering from an infantile-onset neurodegenerative disorder with severe cerebellar atrophy, epilepsy,
dystonia, optic atrophy, and peripheral neuropathy, diagnosed with an homozygous stop mutation
in Thioredoxin 2 (TXN2). TXN2 is a small mitochondrial redox protein essential for controlling
the homeostasis of mitochondrial reactive oxygen species; based on the established defect in ROS
regulation, TXN2 patient was treated with Idebenone (900 mg/day) in a compassionate use. During the
4 months follow-up period the, patient showed an improvement of feeding behavior (less tube feeding
required), a considerable weight gain and increased physical capacity [243].
Idebenone has also been used to treat OPA1-dependent Dominant Optic Atrophy. Dominant optic
atrophy (DOA) arises from heterozygous mutations in the OPA1 gene that promotes fusion of the
inner mitochondrial membrane and plays a role in maintaining ATP levels. Patients display optic
disc pallor, RGC loss, and bilaterally reduced vision [244]. A randomized, placebo-controlled trial of
idebenone at 2000 mg/kg/day in Opa1 mutant mice with visual loss revealed limited therapeutic effects
on RGC dendropathy and visual functions and showed a detrimental effect of idebenone in wild-type
mice [245]. Nevertheless, patients’ results are more encouraging: a pilot study on seven DOA patients
documented encouraging results after 1-year of idebenone administration, with some improvement of
visual function [246]. A recent retrospective cohort study investigated the effect of off-label idebenone
administration on visual outcome in a DOA group of 87 patients, demonstrating that the treatment
was significantly associated with stabilization/recovery of visual acuity [247].
3.7.9. MitoQ
MitoQ is a CoQ10 analogue that contains the antioxidant quinone moiety covalently attached
to a lipophilic triphenylphosphonium cation (TPP+), specifically designed to be accumulated by
mitochondria in vivo, driven by the plasma- and mitochondrial-membrane potential [248]. To enter
mitochondria, alkyl triphenylphosphonium cations first bind to the inner membrane’s outer surface,
then permeate the phospholipid bilayer’s hydrophobic potential energy barrier, before binding to the
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inner surface of the membrane [249]. Once imported into mitochondria, nearly all the molecule is
adsorbed into the IMM matrix surface, where it is continuously recycled to the antioxidant quinol form
by the succinate-CoQ reductase [249,250]. However, MitoQ does not work as an electron carrier because
it is a poor substrate for CI, CIII, and electron-transferring flavoprotein (ETF): quinone oxidoreductase
(ETF-QOR) [250]. The selective accumulation of MitoQ prevents mitochondrial oxidative damage far
more efficiently than untargeted antioxidants, although an intact mitochondrial membrane potential
is required for its efficacy [251]. In vivo studies assessed that MitoQ can be safely administered for
long term treatments [252,253]. Therefore, it has been developed as a pharmaceutical compound by
Antipodean Pharmaceuticals Inc. and tested in few clinical trials to evaluate the beneficial effect of its
antioxidant properties. The PROTECT study (ClinicalTrials.gov identifier: NCT00329056) evaluated
the effect of MitoQ administration on the progression of Parkinson’s Disease, which showed no
significant improvement compared to the placebo group [254]. Some encouraging results have instead
been obtained in age-related vascular dysfunction [255]. Although MitoQ is the most extensively
studied mitochondria-targeted antioxidant in several disease contexts ranging from diabetes [256] to




Modifications of the redox head and lipid tail of the CoQ10 molecule accomplished by Enns and
co-workers [259] led to new experimental, redox-active molecules. Such new drugs, including the
EPI-743, EPI-A0001, EPI-589 work as pro-oxidant, electron shuttles, and also display antioxidant
properties. Importantly, the chemical modifications of the quinone ring, i.e., the substitution of
the two methoxy groups with two methyl groups, significantly increased the redox properties of
EPI-743, which undergo oxidation-reduction at a redox potential offset by −75 mV compared to CoQ10
and idebenone [259]. The changes at the isoprene tail significantly reduce these three molecules’
lipophilicity, thus raising their bioavailability.
EPI-743 (Vatiquinone) is a drug belonging to the class of para-benzoquinones, a group
of potent cellular oxidative stress protectants. EPI-743 targets the enzyme NADPH quinone
oxidoreductase 1 (NQO1), increasing the biosynthesis of glutathione and modulating the redox
control of metabolism [259]. It is an orally bioavailable molecule that can efficiently cross the
blood–brain barrier [259]. The first clinical trial in 2011 enrolled 14 participants, who were selected
based on two criteria: (I) genetically confirmed mitochondrial disease; and (II) possibility of end-of-life
care starting within 90 days. All but one patient had an encephalomyopathy phenotype. Subjects were
treated with EPI-743 orally or via gastrostomy tube for 12 weeks in a subject controlled, open-label study.
Two patients died; the twelve survivors showed a modified disease progression, with a significant
improvement of quality of life, brain imaging parameters, and clinical in >90% of the cases [259].
A prospective single-arm subject-controlled trial of EPI-743 was conducted in 2012 in children with
genetically confirmed Leigh syndrome, at least moderately severe disease and MRI confirmation
of necrotizing encephalopathy [260]. Subjects were treated for six months, with 100 mg of EPI-743
three times daily orally or via a gastrostomy tube. The clinical outcome showed that all children
demonstrated arrested of the disease progression and/or reversal [260]. Analysis of blood samples in
other children with mitochondrial encephalopathy showed EPI-743 administration’s ability to restore
reduced glutathione pools [261]. A recent case report documented the visible improvement of a
pediatric patient with Leigh syndrome due to a mutation in the mitochondrially encoded ND3 gene
treated with EPI-743. She was the only child surviving after four years of age, suggesting that EPI-743
could modify the natural course of the syndrome and contribute to the patient’s long-term survival [262].
In a small open-label trial, EPI-743 arrested disease progression and reversed vision loss in most treated
patients with LHON, suggesting that the previously described irreversible priming to retinal ganglion
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cell loss may be reversed by EPI-743 administration [263]. Other clinical trials evaluating the efficacy
of EPI-743 in mitochondrial disease are still ongoing: one study has recruited 31 patients with Leigh
syndrome to evaluate the long-term safety and neurodevelopmental effects of EPI-743 administration
the dose of 15 mg/kg, up to a total 200 mg three times daily. The estimated primary completion
date is December 2021 (ClinicalTrials.gov Identifier: NCT02352896). Another non-randomized,
double-blind, placebo-controlled, cross-over study has finished recruiting children aged 2–11 with
PMD in 2019. The primary outcome measures the effects of EPI-743 on quality of life. Secondary
outcome measures include various biochemical, imaging, and clinical abnormalities (ClinicalTrials.gov
Identifier: NCT01642056). Other molecules of the EPI series could be applied in the treatment of
PMD due to OXPHOS defect, such as EPI-A0001 and EPI-589 although they have not been tested yet.
EPI-A0001 (α-tocopheryl quinone) is a potent antioxidant, that has been tested for the treatment of
Friedreich ataxia [264]. Only one double-blind, randomized, placebo-controlled, 28-days trial of two
doses of EPI-A0001 in 31 patients reported encouraging results in terms of improvement of neurological
function (ClinicalTrials.gov Identifier: NCT01035671). However, no other further studies have been
reported. EPI-589, also known as (R)-troloxamide quinone, is expected to increase the reserves of
antioxidant molecules, but to date, there are no published data regarding its mechanism of action. It is
currently used for the treatment of ALS and in a clinical trial for Parkinson’s Disease.
3.8.2. JP4-039
The affinity of the antibiotic Gramicidin S for the bacterial membrane has inspired the
chemical structure of the JP4-039 molecule, a new, mitochondrial-targeted antioxidant drug [265].
JP4-039 displayed electron scavenger properties in animal models and in several tumor cell lines, as well
as to improve mitochondrial respiration and scavenge ROS in ACAD9- [266] and in Very Long-Chain
Acyl-CoA Dehydrogenase (VLCAD)- mutant fibroblasts [267]. Similar results have been reported in
ETHE1 and MOCS1 mutant cell lines, in which JP4-039 treatment did increase the oxygen consumption
rate, ATP production, and decrease superoxide levels. Preliminary pharmacokinetics after intravenous
administration suggested fair tissue distribution, including in the brain, opening future perspectives
for mitochondrial neurological disease therapies.
3.8.3. KH176
The ROS-Redox modulator KH176 was developed by the optimization of the Trolox-derivatives
molecules [268]. KH176 has a dual effect: (I) it successfully reduces cellular ROS levels, and (II) it
protects against redox perturbation by targeting the thioredoxin/peroxiredoxin system. The mechanism
of action of KH176 requires its conversion into the quinone metabolite KH176m [268]. KH176 could
counteract the ROS production and mitigate the altered cellular redox state in cellular models of CI
defects [268]. The therapeutic efficacy of KH176 was tested in preclinical models of PMD. Long-term
KH176 treatment ameliorated the clinical phenotype and the brain microstructural coherence of the
CI-deficient Ndufs4 ko mouse model [269,270]; however, no further improvement was observed with
combined treatment with the PPAR agonist clofibrate [270]. A Phase 1 clinical trial in healthy adult
male volunteers deemed that KH176 is well tolerated up to single doses of 800 mg and multiple doses
of 400 mg b.i.d. and has a pharmacokinetic profile supportive for a twice-daily dose (ClinicalTrials.gov
Identifier NCT02544217) [271]. Phase 2, double-blind, randomized, placebo-controlled, single-center,
two-way cross-over trial has also been performed [272] (The KHENERGY STUDY - ClinicalTrials.gov
Identifier NCT02909400). This study recruited patients with m.3242A>G mutation and aimed to explore
the effects of treatment with KH176 for 4 weeks on clinical signs and symptoms and biomarkers of
PMD and evaluate the KH176-related safety and pharmacokinetics. Results confirmed that KH176 was
well tolerated and appeared safe at the 100-mg twice a day dose regimen; a significant improvement of
the patients’ overall mental health status was also documented [272]. Recently, KH176 (Sonlicromanol,
developed by the biopharmaceutical company Khondrion, The Netherlands), received a rare pediatric
disease (RPD) designation from the United States Food and Drug Administration (FDA), for the
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treatment of patients with MELAS syndrome [273]. Sonlicromanol is currently in Phase IIb clinical
development (The KHENERGYZE Study, ClinicalTrials.gov Identifier: NCT04165239).
3.8.4. SKQ1
The mitochondria-targeted antioxidant 10-(6′-plastoquinonyl)-decyl-triphenyl-phosphonium
(SKQ1) is a cationic plastoquinone derivative containing a positively charged phosphonium connected
to plastoquinone by a decane linker. The antioxidant activities of mitochondria-targeted cationic
plastoquinone derivatives (SKQs) are accomplished in two different ways: (I) by preventing
peroxidation of cardiolipin [274] (mediated by quinol moieties) and (II) by fatty acid cycling, resulting in
mild uncoupling that inhibits the formation of ROS in mitochondrial State IV (mediated by cation
moieties) [275]. SKQ1 can effectively mitigate the oxidation induced either by hydrogen peroxide or by
organic hydroperoxide in vitro [276]. SKQ1 has mainly been tested in several pathological cellular and
pre-clinical models in which ROS-mediated mitochondrial dysfunction and cell death play a crucial
role, such as Alzheimer’s Disease [277,278], multiple sclerosis [279], and Parkinson’s Disease [280].
In contrast, only one work tested its efficacy in a PMD model [281]. Shabalina and co-workers reported
that chronic administration of SKQ1 to the Mutator mouse ameliorated mitochondrial ultrastructure in
several tissues and significantly improved age-related phenotypic features, including the occurrence of
hair loss, kyphosis, loss of estrus cycle, body weight loss, reduced lipid stores, hypothermia, immobility,
and torpor-like states. Most importantly, SKQ1 administration significantly increased the lifespan of
the Mutator mice [281]. However, increased oxidative damage has not been observed in the mtDNA
Mutator mice (as reviewed by Edgar and Trifunovic [282]).
3.9. Pharmacological Modulation of Mitochondrial Dynamics
Mitochondria are highly dynamic organelles that undergo coordinated cycles of fission and
fusion, referred to as “mitochondrial dynamics”, to maintain their shape, distribution, and size [283].
Mitochondrial shape and mass are finely tuned by the activity of the pro-fusion proteins Mitofusin 1
(MFN1) and Mitofusin 2 (MFN2)—acting on the outer mitochondrial membrane (OMM)—and optic
atrophy protein 1 (OPA1)—acting on the inner mitochondrial membrane (IMM)—plus the antagonist
action of pro-fission proteins, such as dynamin-related protein 1 (DRP1) and mitochondrial fission
1 protein (FIS1) [284]. OPA1 is a multitasking GTPase with a total of eight long and short isoforms,
which are involved in two independent mechanisms: (I) tighten of mitochondrial cristae of the
IMM [285], that favors MRC supercomplexes assembly and optimizes mitochondrial respiration [286]
(II) elongation of the mitochondrial network, promoting mitochondrial fusion [287]. Modifying these
processes may benefit different PMD [98].
Genetic disorders of mitochondrial dynamics comprise defects of mitochondrial fusion triggered
by mutations in MFN2 or OPA1, exhibiting as Charcot–Marie–Tooth type 2A and autosomal dominant
optic atrophy, respectively [288–290], and impaired mitochondrial fission caused by mutations in
DRP1 [291] and MFF [292]. The observation that the overexpression of OPA1 increased respiratory
efficiency by stabilizing the respiratory chain SC [287] suggested that moderate overexpression of OPA1
could be beneficial in MRC defects models. Significant amelioration of mitochondrial encephalopathy
and myopathy was obtained in a mouse model of COX defect crossed with a transgenic Opa1 mouse
model [293]. Furthermore, Opa1 overexpression also prevented kidney focal glomerulosclerosis in
the Mpv17 ko mouse [294]. The recent discovery of chemical modulators of mitochondrial fusion
(M-hydrazone) and fission (MDIVI-1 and P110) may represent a therapeutic option for OXPHOS
defect [295–297].
Mitochondrial dynamics could be indirectly modulated, targeting the cytoskeleton organization,
which has a significant role in supporting the mitochondrial network [298]. Recently, the Escherichia
coli protein toxin called Cytotoxic Necrotizing Factor 1 (CNF1), which acts on the Rho GTPases
regulators of the actin cytoskeleton [299], was tested in OXPHOS deficient patients‘cells [300].
CNF1 effectively induced mitochondrial elongation, rescuing the wild-type-like mitochondrial
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morphology and increasing the ATP content in fibroblasts derived from a MERRF patient with
m.8344A>G mutation [300]. Further studies are needed to assess the potential use of these drugs on
preclinical models of PMDs.
3.10. Pharmacological Protection of Cardiolipin
Among experimentally new drugs for PMD, there is Elamipretide (also known as MTP-131, SS-31,
and Bendavia), a small aromatic-cationic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that readily
penetrates cell membranes in a non-energy requiring and non-saturable manner, and transiently
localizes to the IMM, where reversibly binds to cardiolipin [301]. Cardiolipin is a unique phospholipid
that is only located on the IMM and plays essential structural roles in modulating the IMM
curvature leading to cristae formation and organizing the electron transport chain complexes into
SC to facilitate optimal electron transfer and energy production. Cardiolipin also plays a role in
anchoring cytochrome c to the inner membrane facilitating electron transfer from CIII to CIV [302].
When oxidized, cardiolipin participates in cell death. It is highly vulnerable to oxidative damage
because it contains many unsaturated fatty acids and is located close to reactive oxygen species’
production site. Oxidation of cardiolipin leads to the disruption of intimal microregions and the loss of
membrane curvature and cristae [303]. Elamipretide binds selectively to cardiolipin via electrostatic
and hydrophobic interactions and protects it from oxidation, keeping mitochondrial cristae, promoting
oxidative phosphorylation, and inhibiting mitochondrial permeability transition pore opening [205].
The idea is that elamipretide restores energy production, reduces the production of reactive oxygen
species, and ultimately increases the energy supply to affected cells and organs. It has been shown that
elamipretide consistently improves mitochondrial, cellular, and organ function in both in vitro and
in vivo disease models for which mitochondrial dysfunction is understood to be an essential component,
including cardiovascular, renal, metabolic, skeletal muscle, neurodegenerative, and mitochondrial
genetic disease [304–308].
Elamipretide is metabolized via sequential C-terminal degradation to the tripeptide M1 and the
dipeptide M2. The apparent plasma half-life (t 12 ) of M1 was comparable to that of elamipretide,
whereas t 12 of M2 was longer than that of elamipretide. elamipretide and its metabolites are
excreted primarily through the kidneys. Elamipretide was initially used in preclinical models
to treat ischemia/reperfusion injury, a common complication of interventional procedures for acute
myocardial infarction and coronary bypass surgery [309].
As of November 2017, the U.S. FDA Office of Orphan Products Development has granted
Orphan Drug Designation to Stealth’s investigational drug candidate, elamipretide, to treat
patients with primary mitochondrial myopathy (MM). SPIMM-301 was a Phase 3, multicentered,
double-blind, parallel-group, placebo-controlled trial followed by an open-label treatment extension
(ClinicalTrials.gov Identifier: NCT03323749). It evaluated the efficacy and safety of elamipretide
over 32 weeks in 218 patients, ages 16 to 80, with MM. Enrolled subjects received in Part 1 single
daily 40 mg/mL subcutaneous injections of fixed doses of elamipretide/placebo for up to 24 weeks;
in Part 2 received single daily 40 mg/mL subcutaneous injections of fixed doses of elamipretide
for up to 144 weeks. The trial was conducted at 28 clinical sites across North America, Europe,
and Australia. The primary endpoints assessed efficacies were the 6-min walk test (6MWT) and the
Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score. The 6MWT
measures the distance an individual can walk over a total of 6 min on a hard, flat surface. PMMSA is
a patient-reported outcome tool developed by Stealth in which individuals with PMM report their
fatigue, muscle weakness, and other symptoms on a scale from 1 (least severe) to 4 (most severe).
Safety results showed that treatment with elamipretide was well-tolerated with most adverse events
mild to moderate in severity, but it did not produce significant improvements in 6MWT and PMMSA
assessments [310].
Elamipretide is now in late-stage clinical studies in other three PMD: Barth syndrome
(ClinicalTrials.gov Identifier: NCT03098797), Leber’s hereditary optic neuropathy (ClinicalTrials.gov
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Identifier: NCT02693119), as well as a clinical study in dry age-related macular degeneration (AMD)
with non-central geographic atrophy (ClinicalTrials.gov Identifier: NCT03891875).
3.11. Pharmacological Modulation of Autophagy
Autophagy is an evolutionarily conserved process that degrades cargoes-like aggregate-prone
proteins, pathogens, damaged organelles, and macromolecules via delivery to lysosomes, to warrant
cellular quality control. Targets for degradation are first encircled into specific, double-membrane
structures termed autophagosomes, whose formation (phagophore), elongation, and closure are
controlled by autophagy-related (ATG) proteins [311]. Autophagosomes are fused with lysosomes
to generate autophagolysosomes that carry out the degradation of the substrates. Stimulation of
autophagy has been proposed as a therapeutic approach to target and eliminate dysfunctional
mitochondria. The most widely used inhibitor of (macro) autophagy is rapamycin, which acts by
blocking the target of rapamycin (mTOR) complex 1 (mTORC1) [312]. Johnson and co-workers
first published the results of a chronic treatment of a PMD mouse model with the mTOR inhibitor
Rapamycin in 2013. The authors reported a significant delay in the disease progression and fatal
outcome of the Ndufs4 ko mouse [313]. These results were further confirmed in other preclinical models
of OXPHOS, including (I) a muscle-specific Cox15 ko mouse [314], (II) an ND2-deficient Drosophila
model of LS [315], (III) iPSCs-derived neurons carrying a mutation in the MT-ATP6 gene [316],
and (IV) the gas-1 (fc21) nematodes [317]. These encouraging results led to developing a clinical
study (ClinicalTrials.gov Identifier: NCT03747328) in four MELAS patients treated with Everolimus,
a rapamycin analogue. Patients’ derived primary fibroblasts showed improvement of mitochondrial
morphology, membrane potential, and replicative capacity [318]. Recently, Everolimus was used to treat
two children affected by Leigh disease or MELAS. The latter failed to respond and died of progressive
disease 10 months after starting the treatment [319], whereas the child with Leigh syndrome improved
health status. Brain MRI reduced the bilateral signal hyperintensity in thalami and brainstem after 6
months of treatment. Further improvements were documented after 19 months of treatment, being
the patient able to walk independently with a slightly ataxic gait, and with no longer required of
tracheostomy and gastrostomy. However, although these data support the idea that rapamycin may
be useful in several PMD, others recently reported that rapamycin treatment exacerbated the disease
progression in mice with CoQ10 deficiency [320] and failed to rescue the cerebral pathological features
of TwKOastro mice [59], indicating that not all metabolic defects may benefit from rapamycin therapy.
Moreover, mTORC1 inhibitors are linked to immunosuppressive outcomes [321], and it is currently
unknown whether this effect could be detrimental for PMD patients in the long-term.
3.12. Bypassing cI-cIII-cIV Defects with Alternative Enzymes
A recent therapeutic strategy concerns the possibility to by-pass OXPHOS defects by using
the alternative enzymes NADH dehydrogenase/CoQ10 reductase (NDI1), plant alternative NADH
dehydrogenases (NDH-2), and CoQ10/O2 alternative oxidase (AOX). AOX and NDI1 are single-peptide
enzymes present in yeast, plants, and lower eukaryotes where they act as alternative components
of the respiratory chain. NDI1 substitutes CI in yeast, where it transfers electrons to CoQ10 and
regenerates the NAD+ pool, while AOX bypasses CIII and CIV by accepting electrons from CoQ10.
In contrast to Saccharomyces Cerevisiae NDI1, which enzymatically competes with endogenous CI [322],
plant alternative NDH-2 naturally coexists with endogenous CI and supports the oxidation of
NADH only in specific physiological conditions [323], e.g., when CI is metabolically inactive, or the
concentration of matrix NADH exceeds a certain threshold. It should be noted that such alternatives
electron transfer activities are not linked to a proton pumping across the inner mitochondrial membrane.
Expression of these enzymes has been used to bypass CI deficiency in Drosophila melanogaster [324],
combined CI-III-IV deficiencies in ρ0 mouse cells [325], CIII-IV deficiencies in human cells [326] and
Drosophila melanogaster [327], raising the possibility to use these genes to treat OXPHOS-related disorders.
Adeno-associated virus (AAV) expressing NDI1 (AAV-NDI1) was shown to protect retinal ganglion
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cells (RGCs) in a rotenone-induced murine model of LHON, significantly reducing RGC death by
1.5-fold and optic nerve atrophy by 1.4-fold and considerably preserving retinal function [328]. Recently,
the effects of the expression of NDI1 in vivo have been tested in a mouse model of Leigh syndrome
due to the lack of the 18-KDa complex I subunit Ndufs4 [329]. McElroy and co-workers generated a
mouse that conditionally expressed the yeast NDI1, while the Ndufs4 was lost, specifically in the brain.
NDI1 expression was sufficient to dramatically prolong lifespan without significantly ameliorate the
ataxic phenotype [329].
Interestingly, the authors demonstrated that mitochondrial CI activity in the brain supports
organismal survival through its NAD+ regeneration capacity, while optimal motor control requires
the bioenergetic function of mitochondrial CI [329]. When transgenic Ciona intestinalis AOX mice
were crossed with CIII-deficient Bcs1lp.S78G knock-in mice—a model of GRACILE syndrome (growth
retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis, and early death) [330,331],
with multiple visceral manifestations and premature death—AOX expression was able to increase
lifespan, prevent lethal cardiomyopathy, and ameliorate renal and cerebral manifestations. On the
contrary, when the transgenic AOX mouse was crossed with the Acta-Cox15 ko model, the double
ko-AOX mutants showed a decreased lifespan and a substantial worsening of the myopathy compared
to the ko alone. Decreased ROS production in ko-AOX versus ko mice led to impaired AMPK/PGC-1α
signaling and PAX7/MYOD-dependent muscle regeneration, blunting compensatory responses [332].
Recently, the two different mitochondrially-targeted NDH-2 (AtNDA2 and AtNDB4) from
Arabidopsis thaliana (At) were used to bypass the OXPHOS defect in human CI deficient fibroblasts and
reduce oxidative stress [333].However, a competition between AtNDA2 and endogenous CI for NADH
oxidation was reported in control cell lines [333], raising some concern about its potential therapeutic
application for human PMD.
4. Precision Medicine Approaches for PMD Caused by mtDNA Defects
4.1. Pre-Implantation Therapies to Prevent the Transmission of mtDNA Mutations
Each mammalian cell contains numerous copies of mtDNA. The coexistence of mutated and
wild-type mtDNA molecules is called heteroplasmy, the percentage of which can range from
negligible values to 100%. Heteroplasmy allows detrimental mutations to persist, and most
importantly, to be transferred to the next generation. MtDNA molecules segregate unequally during
primordial germline development. Upon oocyte maturation, such segregated pools of mtDNA expand
within each egg cell. In the case of an asymptomatic mother carrying heteroplasmic mutations
in her germline, the heterogeneous population of oocytes could develop offspring with vastly
varying levels of heteroplasmy [334]. Therefore, pathogenic mutations of mtDNA are maternally
transmitted [335] although a rare, paternal inheritance was debated in the last years, and recently
reviewed by Wei and Chinnery [336]. Heteroplasmy is well tolerated until the percentage of the
mutation (i.e., mutational load) exceeds a certain threshold, often greater than 60% mutated mtDNA,
beyond which bioenergetic defect manifests, mainly in high energy demanding tissues. No effective
therapies for mtDNA-linked disease exist, and several techniques can prevent the transmission of
pathogenic mutations.
4.1.1. Pre-Implantation Genetic Diagnosis
Pre-implantation genetic diagnosis is a preventive approach that still represents families’ best
option with a known story of mtDNA mutations [337]. Pre-implantation diagnosis is an in vitro
fertilization (IVF)-based approach in which the fertilized egg harboring the pathogenic mtDNA
mutation is cultured until the stage of 6–8 cells [338] or blastocyst [339] and then biopsied for genetic
analysis before implantation. However, the pre-implantation diagnosis has some limitations: (I) it will
only benefit women who have low levels of mtDNA mutations in oocytes [340] and, (II) it assumes
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that the diagnosed heteroplasmy level is representative of that of the entire embryo and would not
change over time.
4.1.2. Mitochondrial Donation: Maternal Spindle Transfer
Recently, mitochondrial replacement or mitochondrial donation (MD) has been proposed as a
potential method for preventing transmission of mutated mtDNA from the mother to the offspring,
by replacing the mitochondria in the oocytes of carrier women. The most recently exploited MD
reproductive technologies include maternal spindle transfer (MST) [341] and pronuclear transfer
(PNT) [342]. This technology is legally approved for use in the U.K., but the governments of Australia
and Singapore are in the process of formal discussions aimed at MD legalization. However, the current
state of MD-relevant activity and regulation remains largely elusive in many countries; please refer
to [343] for a detailed overview. MST is a complex technique that involves the transfer of nuclear
genetic material between a patient’s egg with mutated mtDNA to an enucleated donor’s unfertilized
metaphase II oocyte with healthy mitochondria. MST generates an oocyte with a patient’s nuclear
DNA devoid of mutated mtDNA. MST is then followed by intracytoplasmic sperm injection (ICSI)
and in vitro embryo culture (Figure 3A). A proof-of-principle use of MST to prevent the transmission
of mutated mtDNA molecules was first reported in rhesus macaques by the group of Mitalipov in
2009 [344]. In that case, MST and subsequent ICSI resulted in the birth of healthy offspring (named Mito
and Tracker) with undetectable levels of spindle donor’s associated mtDNA [344]. The same group then
translated this technique to human oocytes, and similar fertilization and blastulation rates between MST
and control groups were observed, suggesting that embryo development was not compromised [345].
MtDNA analysis revealed that all examined spindle transfer zygotes and cleaving embryos contained
more than 99% donor mtDNA. Similar outcomes were observed in 87% of embryonic stem (ES) cell
lines established from spindle transfer blastocysts, regardless of donor mtDNA. However, a reversal
of mtDNA haplogroup from donor to maternal mtDNA in a limited number of ES clones was
reported, for which a mechanistic explanation based on replicative advantages conferred by some
D-loops polymorphisms were proposed [345]. It should be noted that a further mtDNA analysis on
those and others ES cell lines [346] raised some concerns about the evidence provided by Kang and
co-workers [345]. At the American Society for Reproductive Medicine (ASRM) annual meeting 2016,
Dr. John Zhang, New Hope Fertility Center of New York City reported the outcome of the use of MST
in a woman carrying mtDNA mutation of Leigh syndrome (8993 T>G), which resulted in the birth
of an healthy baby with less than 10% mutated mtDNA in tissues tested 2 days after the birth [347].
A case report was published in 2017 [348].
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4.1.3. Mitochondrial Donation: Pronuclear Transfer
The pronuclear transfer (PNT) involves a first step of in vitro fertilization of the patient’s oocyte,
followed by the removal of the diploid nucleus, which is then transferred into a donor’s enucleated
zygote with healthy mitochondria (Figure 3B) [340]. PNT was proposed in 2005 to prevent transmission
of mtDNA disease in the mito-mouse, a model that accumulates large-scale mtDNA deletions [349].
In this elegant paper, second polar bodies were used as biopsy samples to diagnose mtDNA genotypes
of mito-mouse zygotes. Nuclear transplantation was carried out from mito-mouse zygotes to enucleated
normal zygotes and was shown to rescue all of the F(0) progeny from the expression of respiration
defects throughout their lives [349]. In a second report published in 2010, abnormally fertilized human
zygotes were used, and reconstructed embryos developed following PNT showed the capacity to reach
the blastocyst stage [340]. In 2016, the first preclinical evaluation of PNT using normally fertilized
human embryos was reported [350]. Since the techniques used these studies [340] were not tolerated
by normally fertilized zygotes, an alternative approach was developed, that significantly improved
the efficient development to the blastocyst stage. This was based on performing the pronuclear
transplantation immediately after completing meiosis rather than before the first mitotic division.
Following this optimization, mtDNA carryover was reduced to less than 2% in the majority (79%) of
PNT blastocysts. The study reported low levels of mtDNA carryover in PNT embryos and observed a
reversion to the maternal haplogroup in a limited number of hESC clones derived from PNT inner cell
mass embryos [350]. In conclusion, although PNT can reduce the risk of mtDNA disease, it may not
guarantee prevention [350].
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4.2. Personalized Therapies for mtDNA Disorders
4.2.1. Delivery of Nucleic Acids to the Mitochondria
Mutations in mitochondrial genes or mitochondrial tRNAs are associated with a variety of
maternally inherited neuromyopathies. An effective therapy would imply delivery therapeutic genes
or tRNAs to the mitochondrial matrix, where mtDNA resides.
Nucleic acid delivery into the mitochondrion has been attempted using liposome-based
nanocarriers such as Mito-Porter [351,352] and dequalinium-based liposome-like vesicles
(DQAsomes)-transfection system [353], or by RNA Import Complex [354]. Mito-Porter is a
liposome-based carrier that introduces macromolecular cargos into mitochondria via membrane
fusion. The authors provided evidence of nucleic acid delivery into the mitochondrial matrix either in
isolated rat liver mitochondria and in living, intact cells [351]. As proof of principle, this method was
further exploited to deliver wild-type mitochondrial pre-tRNAPhe to decrease the mutation rate of
tRNAPhe in mitochondria of the patient’s cell with a G625A heteroplasmic mutation in the tRNAPhe of
mtDNA, with a significant correction of the mutation rate [355]. Similarly, a therapeutic correction of
ND3 mutant fibroblasts’ mitochondrial respiration was obtained by reintroducing the wt mRNA of
ND3 via Mito-Porter [356].
DQAsomes are the prototype for all mitochondria-targeted vesicular pharmaceutical nanocarrier
systems. First described in 1998, they have been successfully explored to deliver DNA and
low-molecular-weight molecules to mitochondria within living mammalian cells [357].
The RNA Import Complex (RIC) is a multi-subunit protein complex from the mitochondria of
the Kinetoplastid protozoon Leishmania tropica that induces the transport of tRNA across natural and
artificial membranes [358]. Observing that Kinetoplastid protozoa have evolved specialized systems
for importing nucleus-encoded tRNAs into mitochondria, the RIC was used to import endogenous
cytosolic tRNAs, including tRNALys, and restored mitochondrial function in wild-type, MERFF,
and KSS cybrids [354].
However, no effective treatment was translated into animal models despite this evidence of
delivering the exogenous nucleic acids into the cellular mitochondria.
4.2.2. Heteroplasmic Shift
A second strategy to correct mtDNA mutations is based on the disruption of mutant molecules
using selective nucleases to shift the heteroplasmy level below the critical, pathological threshold.
To this aim, several approaches based on the following tools have been developed in the past years and
are discussed below: (I) restriction enzymes; (II) antisense oligonucleotides; (III) molecular scissors;
(IV) DddA.
The very first work carried out by Tanaka and co-workers in 2002 [359] implied the delivery of
the restriction endonuclease SmaI into the mitochondria of cybrids to specifically degrade mtDNA in
which the pathogenic 8993T>G mutation was present, creating a specific SmaI-restriction site [359].
SmaI specifically degraded mutant mtDNA, with consequent repopulation of mitochondrial genome
by wild-type molecules, and subsequent restoration of intracellular ATP level and mitochondrial
membrane potential [359].
Heteroplasmy shifting has also been achieved using antisense oligonucleotides in cybrids
containing a heteroplasmic mtDNA deletion [360]. In this case, anti-replicative RNA molecules
were designed and transfected into a cybrid cell line derived by a KSS patient’s fibroblasts carrying
an mtDNA deletion involving 65% of the mtDNA molecules. The anti-replicative effect of the RNA
oligoribonucleotides complementary to the mutant mtDNA region specifically reduced the proportion
of pathological mtDNA population, shifting the heteroplasmy level from 65% to 50% [360].
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology has
been largely used for nuclear gene editing; however its application for the editing of the mitochondrial
genome appears highly challenging mainly due to sub-efficient delivery of guide RNA and Cas9
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enzyme complexes into mitochondria. However, in 2015, Jo and colleagues successfully manipulated
the mtDNA with the CRISPR/Cas9 technology [361]. Despite the lack of MTS peptides, the authors
showed that the flagged Cas9 localized into the mitochondria, while the gRNAs allowed specific
depletion of targeted portions of mtDNA but not degradation of the entire molecule. This point was
difficult to reconcile with the fact that mtDNA behaves as a unit [362].
A recent preprint study reported the editing of the MT-ND4 gene accomplished by targeting the
guide RNA to an RNA transport derived stem loop element (RP-loop), while expressing the Cas9
enzyme with a mitochondrial localization sequence [363]. However, due to the controversial nature of
mammalian mitochondrial RNA import [364], the use of the CRISPR/Cas9 application for mtDNA
editing is still debated.
Very recently, adeno-associated viral vectors (AAVs) were used to deliver molecular scissors
(i.e., ZFNs, mitochondrial-targeted (mt) TALENs and mtZFNs) in vivo, to destroy mutated mtDNA
selectively. Using the first available mouse model of heteroplasmic mitochondrial disease, bearing the
point mutation m.5024C>T in mitochondrial tRNAALA (mt-tRNAALA) [365], both TALENs and mtZFNs
were able to reduce the mtDNA heteroplasmy with the concomitant rescue of molecular and biochemical
phenotypes [366,367].
However, the approaches described so far cannot introduce specific nucleotide changes in mtDNA
and cannot be applied to homoplasmic mtDNA mutations because they would destroy all mtDNA
copies. To overcome those issues, Mok et al. has recently set up a precision genome editing strategy.
They obtained outbreaking results using the interbacterial toxin “double-stranded DNA deaminase
toxin A”, or DddA, encoded by Burkholderia cenocepacia, which catalyzes the deamination of cytidines
within dsDNA [368]. Engineered split-DddA halves are inactive until simultaneously carried on the
target DNA by adjacently bound programmable DNA-binding proteins. The fusions of the split-DddA
halves, transcription activator-like effector (TALE) array proteins, and an uracil glycosylase inhibitor
generated the RNA-free DddA-derived cytosine base editors (DdCBEs), which allows guided CG-to-TA
changes in mtDNA without the need of double-strand breaks. This technique can potentially correct
pathogenic mutations on mtDNA with high levels of purity and specificity [368]. Despite these findings
looking extremely innovative, additional research aimed to improve the delivery of DdCBEs in vitro
and in vivo is essential for exploring their therapeutic potential.
4.2.3. Allotopic Gene Expression
Allotopic gene expression is a method to overcome the mtDNA mutations by re-expressing
the missing mtDNA-encoded protein from the nucleus. In this case, an engineered nuclear version
of a mitochondrial gene encodes a protein that can be imported into the mitochondria due to an
MTS presence. This approach was used to deliver the protein product of the MT-ATP6 gene to
the mitochondria in cybrids containing the m.8993T>G mutation [369]. Such allotopic expression
significantly improved the cell growth in selective medium and the ATP synthesis [369]. Similarly,
allotopic expression of the MT-ND4 gene effectively prevented blindness in a rat model of LHON [370].
Consequently, a human clinical trial of gene therapy to treat LHON has been carried out. Although
there was weak evidence of allotopic expression, Guy et al. reported the amelioration of visual acuity
in the injected eyes [371]. Another clinical trial (ClinicalTrials.gov identifier NTC01267422) in which
nine patients affected by LHON carrying the G11778A mutation were treated with a single dose
(5 × 109 vg/0.05 mL) of rAAV2-ND4 reported no adverse effects. In six out of nine patients, the injected
eyes’ visual acuity improved by at least 0.3 log MAR after nine months of follow-up. The visual
field was enlarged, but the retinal nerve fiber layer remained relatively stable. The visual acuity
improved, and the visual field was enlarged nine months after treatment, while other parameters were
unchanged [372]. A third open-label phase I/II clinical trial (ClinicalTrials.gov identifier NCT02064569)
investigated both safety and preliminary efficacy of a rAAV2/2-ND4 in four dose-escalation cohorts.
The treatment resulted in safe with mild adverse effects. Six out of 14 patients manifested a clinically
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relevant improvement in the best-corrected visual acuity. Taken together, these results suggest the
possible use of gene therapy for LHON.
4.2.4. Mitochondrial Augmentation Therapy
Recently, Minovia Therapeutics developed a novel form of cellular therapy called Mitochondrial
Augmentation Therapy (MAT). Its rationale is based on the capability of exogenous mitochondria
to enter cells in culture [373,374], bringing their own genetic material, augmenting endogenous
mitochondrial function, and content and fusing with the endogenous mitochondrial network.
The mitochondrial uptake process was termed mitochondrial augmentation and is currently proposed
for Kearns–Sayre syndrome (KSS) and Pearson Syndrome. KSS is a progressive retinitis pigmentosa and
external ophthalmoplegia occurring at childhood due to de-novo mtDNA deletions [13]. Other systems
may be involved over time, including hearing, heart, skeletal muscles, central nervous system,
endocrine glands, and kidneys [13]. Pearson Syndrome is a rare disorder affecting the bone marrow
and exocrine pancreas [14], also characterized by de-novo mtDNA deletion [15]. MAT approach
enriches hematopoietic stem cells (HSCs) with healthy mitochondria before transplantation in patients.
MAT involves a series of complex steps: first, mitochondria are extracted from white blood cells derived
from the patient’s mother (confirmed non-deleted); in turn, stem cells are collected from the patient,
who receives treatment with Neupogen (filgrastim, by Amgen) to boost the production of white blood
cells in the bone marrow, and with Mozobil (plerixafor, by Sanofi-Aventis) to mobilize the hematopoietic
stem cells containing the CD34 protein marker into the bloodstream. The healthy mitochondria are then
introduced into patient-derived stem cells and given back to the patient by intravenous infusion. A first
human study was performed on three children with Pearson syndrome under a compassionate use
program. Results were reported at the “Targeting Mitochondria Conference 2019” and at “Mitochondrial
Medicine 2019 Meeting”. Mitochondrial augmentation therapy improved the in vitro PS-derived HSC
function, the metabolic determinants, the aerobic capacity, and the quality of life of the treated patients.
The same company also promoted an open-label study (ClinicalTrials.gov identifier NCT03384420) to
assess the MAT’s safety and therapeutic effects. Recruitment of seven children is now in progress to
analyze any treatment-related adverse events at one year, and any improvement in the quality of life,
as assessed by the International Pediatric Mitochondrial Disease Scale.
Moreover, promising results of the first MAT treatment on a KSS patient were recently reported.
The 14-year-old patient underwent leukapheresis, and positively selected CD34+ cells were augmented
with maternal mitochondria before infusion (2 × 106 cells/kg). Then, the patient was followed for
clinical and metabolic parameters. Before MAT, she weighed only 19 kg, she could not sit, walk,
express words, and experienced 1 or 2 seizures a week. Seven months after treatment, she gained
weight, she could reach objects, sit independently, walk with assistance, and express herself in short
sentences. Seizures were resolved 4 months after treatment. Her normalized functional score on
the International Pediatric Mitochondrial Disease Score improved from 91% to 57%. Also, the ATP
content of the peripheral blood lymphocytes was increased. Those impressive improvements of her
physiological and metabolic status make MAT a potential therapy for KSS [375].
5. Precision Medicine Approaches for PMD Caused by Nuclear Defects
5.1. Gene Therapy Approaches
Gene therapy is the most straightforward option for treating disease caused by a single recessive
genetic defect. Re-expressing the wild-type form of a mutated gene, or other therapeutic genes,
using appropriate viral vectors is an attractive strategy, currently exploited for disorders affecting a
single organ. In fact, while the expression of an ectopic gene in the whole body is still unfeasible,
specific critical cells or tissue can be targeted with currently available technologies. AAVs are emerging
as a suitable delivery method because they are not associated with any disease in humans or animals and
remain episomic in the cells for a prolonged time, thus reducing the risk of insertional mutagenesis [376].
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Moreover, the availability of several serotypes allows tissue-specific targeting [377]. Potential pitfalls
concern the limited cloning capacity, the difficulty in achieving therapeutic expression levels in several
tissues—especially skeletal muscle, due to is abundance and distribution- and the brain, due to the
low blood–brain-barrier (BBB) penetrance. One of the first preclinical gene therapy studies applied to
a mitochondrial myopathy was performed using the AAV2 carrying the ANT1 cDNA in the ANT1
ko mouse model. ANT1 encodes the mitochondrial adenine nucleotide translocator, an integral IMM
protein that forms homodimers or tetramers [378], acting as electrogenic pumps that export ATP out
across the IMM in exchange for cytosolic ADP [379]. Mutations in ANT1 lead to MM with progressive
external ophthalmoplegia (PEO), caused by paralysis of the extraocular eye muscles [380]. AAV-ANT1
transduction resulted in long-term stable expression in muscle precursor cells and differentiated muscle
fibers. The transgenic ANT1 protein was targeted into the IMM, formed a functional ADP/ATP carrier,
increased the mitochondrial export of ATP, and reversed the histopathological changes associated with
the MM [381]. Furthermore, the efficacy of AAV-mediated gene therapy has been confirmed in several
mouse models of mitochondrial disorders, including the models for hepato-cerebral forms of severe
mtDNA depletion syndrome [57] and Leigh syndrome [382].
5.2. Liver Transplantation
Liver transplantation (LT) is a feasible approach to treat PMD, mainly affecting the single
organ [383]. LT has been performed in individuals with hepatocerebral forms of mtDNA depletion
syndromes, which frequently progress to liver failure, as those due to mutations in MPV17 gene [384].
However, LT outcome has not been satisfactory, since almost fifty percent of the transplanted patients
died in the post-transplantation period due to multiorgan failure. For this and other reasons, LT in
mitochondrial hepatopathies remains controversial. LT is not recommended in patients with disorders
characterized by a rapid progression of neurological manifestations, such as Alpers–Huttenlocher
syndrome, but it may be beneficial in patients with an acceptable quality of life. LT may also
differentially affect survival, e.g., patients with mtDNA depletion syndromes caused by mutations in
DGUOK gene—encoding the mitochondrial deoxyguanosine kinase, which phosphorylates purines
to the corresponding nucleotides in the mitochondrial nucleotides salvage pathway—show lower
survival than those of patients with other PMD. Although a recent retrospective study on 12 PMD
patients receiving LT confirmed these findings [385], others suggest that, even in the presence of
neurological MRI findings, but in the absence of significant neurological symptoms, LT represents a
viable option in DGUOK-deficient patients [386].
5.3. PMD Characterised by Systemic Accumulation of Toxic Compounds
5.3.1. Application of Gene Therapy Protocol
AAV therapy has been successfully achieved by targeting the missing gene to the liver when
the underlying disease mechanism is linked to toxic compounds’ systemic accumulation. This is
the case of the ethylmalonic encephalopathy caused by mutations in the ETHE1 gene encoding
for a mitochondrial sulfur dioxygenase involved in the detoxification pathway of hydrogen sulfide
(H2S) [387]. Mutations in ETHE1 lead to systemic accumulation of H2S, which acts as a potent inhibitor
of complex IV [197], leading to the onset of the phenotype (for a detailed description of the H2S
pathway, see Viscomi, Bottani et al., 2015 [388]). The re-expression of the ETHE1 gene by a hepatotropic
AAV2/8 serotype restored the missing enzymatic activity in the liver, with a significant clearance of
H2S from the bloodstream, a major amelioration of the phenotype and prolonged lifespan of the Ethe1
ko mice [389]. Similarly, systemic accumulations of thymidine and deoxy uridine, which interfere with
mtDNA replication and lead to mitochondrial dysfunction were corrected by hepatotropic AAV2/8
vector carrying the human TYMP in a mouse model of MNGIE [390]. The nucleoside reduction
achieved by this treatment prevented deoxycytidine triphosphate (dCTP) depletion, which is the
limiting factor affecting mtDNA replication in this disease [390].
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AAV treatment may be useful also in mitochondrial neurodegenerative disorders: it was reported
that the administration of AAV9 carrying the human NDUFS4 partially rescued the phenotype of Ndufs4
ko mice only when simultaneously administered systemically and intracranially. AAV9 serotype did
not efficiently cross the BBB, and mainly targeted glial cells when injected intracranially in new-borns.
Interestingly, newly engineered serotypes AAV-PHP.eB and AAV-PHP.S showed great promises in their
efficiency to transduce the central and peripheral nervous systems, crossing the BBB [391].
5.3.2. Application of Liver Transplantation Protocol
Like the gene therapy approach, the liver is an attractive target for pathologies triggered by systemic
accumulation of toxic compounds. LT is proposed as an alternative approach to treat mitochondrial
neurogastrointestinal encephalopathy (MNGIE) disease. MNGIE is caused by a deficiency of thymidine
phosphorylase (TP) due to mutations in the nuclear gene TYMP [392]. TP is a cytosolic enzyme
catalyzing the first step of thymidine (dThd) and deoxy uridine (dUrd) catabolism. Mutations in TYMP
lead to the accumulation of dThd and dUrd systemically, which induce an imbalance of the cytosolic
nucleotide pool. Because the mitochondrial nucleotide pool relies, in part, on nucleotides imported
from the cytosol, an imbalanced cytosolic nucleotide pool lead to an imbalanced mitochondrial
nucleotide pool, which ultimately has mutagenic effects on mtDNA, resulting in depletion, multiple
deletions, and point mutations causing progressive mitochondrial deficiency and organ failure [392–394].
LT rapidly normalized serum levels of toxic nucleosides in a 25-year-old MNGIE patient, and his
conditions were stable after 400 days of follow-up [395]. LT also resulted in an effective option to
treat ethylmalonic encephalopathy due to mutation in ETHE1 gene [396,397], since the replaced organ
can substitute the deficient ETHE1 enzyme and clear the toxic H2S that accumulate in this disorder,
constituting a feasible therapeutic option in patients. Patients showed progressive improvement of the
neurological functions and normalization or amelioration of the biochemical abnormalities [396,397].
However, the decision to perform LT remains difficult because neurological manifestations may worsen
despite their absence before the transplant [398].
5.3.3. Cell Replacement
Cell therapy consists of using cells or cell-based products to replace dead or defective cells to restore
the function of the affected tissue(s) [399]. Again, this approach has been proposed to treat MNGIE.
While TP is not expressed in all tissues, cellular and plasmatic dThd and dUrd levels are in equilibrium
among all body compartments. Therefore, replacing the lost enzyme in a circulating form—i.e., in the
blood cells—should favor the catabolism of the toxic metabolites in plasma, thus clearing these
freely diffusible substrates from the tissue compartments, normalizing the cellular nucleotide pools,
and preventing further mtDNA damage.
Cell replacement therapies may offer a permanent cure to MNGIE. They comprise (I) Allogeneic
Hematopoietic Stem Cell Transplantation (AHSCT) and (II) erythrocyte-encapsulated thymidine
phosphorylase (EE-TP). Clinical and biochemical improvements following AHSCT have been reported
in MNGIE patients [400,401]. Although AHSCT corrects biochemical abnormalities and improves
gastrointestinal symptoms, the procedure is risky for subjects in poor medical conditions, as many
MNGIE patients are. Since transplant-related morbidity and mortality increases with the progression
of the disease and the number of comorbidities, MNGIE patients should be submitted to AHSCT when
they are still relatively healthy, to minimize the complications of the procedure [401].
EE-TP consists of the ex-vivo encapsulation of Escherichia coli TP within the patient’s autologous
erythrocytes using a reversible hypo-osmotic dialysis process. Once inside the erythrocyte,
the encapsulated enzyme catalyzes the deoxyribonucleosides’ metabolism to the specific products
thymine and uracil, which then exit the erythrocyte and flow into their physiological metabolic
pathways. Recently, three adult MNGIE patients received escalating intravenous doses of EE-TP.
EE-TP was well tolerated, and reductions in the disease-associated plasma metabolites, thymidine,
and deoxy uridine were observed. Clinical ameliorations, including weight gain and improved
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disease scores, were observed in two patients, suggesting that EE-TP can reverse some aspects of
the disease [401]. Advantages of the EE-TP are the prolonged circulatory half-life of the enzyme and
the minimization of the immunogenic reactions compared to those frequently observed in enzyme
replacement therapies administered by the conventional route [401].
5.4. Molecular Bypass Therapy in Disorders of mtDNA Instability
Syndromes characterized by mtDNA instability are usually due to mutations in nuclear genes
involved either in the mtDNA replication machinery or deoxynucleotide triphosphate (dNTP)
metabolism consequently affecting OXPHOS activities.
From the clinical perspective, these diseases are characterized by disorders that range from
severe infantile hepatocerebral encephalopathy to childhood-onset myopathy or adult-onset PEO [402].
The TK2 gene provides an example. The protein product of this gene is a deoxyribonucleoside
kinase with mitochondrial localization that specifically phosphorylates thymidine, deoxycytidine,
and deoxyuridine. This enzyme is required for mtDNA synthesis. Recessive mutations in the human
TK2 gene are responsible for the myopathic form of the mitochondrial depletion/multiple deletions
syndrome [403]. Mitochondrial dNTPs pools are supplied either by de novo synthesis and import from
the cytosol or by the mitochondrial deoxyribonucleoside salvage pathway [404]. Supplementation of the
missing or insufficient dNTP may bypass the block restoring the deoxynucleotides triphosphate (dNTP)
pools. Molecular bypass therapy (MBP) with deoxypyrimidine monophosphates (dCMP and dTMP)
or substrate enhancement therapy with deoxypyrimidine nucleosides (dC and dT) were tested on the
Tk2 knock-in (ki) mouse model in the early pre-symptomatic, but biochemically affected, stage [405].
Treatment with dCMP and dTMP raised dTTP concentrations, increase levels of mtDNA, ameliorated
the defects of MRC enzymes, and significantly prolonged the lifespan (from 13 to 34 days) in a
dose-dependent manner [406,407]. Late treatment of 29-day-old mice was ineffective.
Similar strategies were then extended in different models of PMD. The mtDNA depletion
in human fibroblasts mutated in the DGUOK gene was ameliorated by the supplementation of
deoxyguanosine [404], and similarly, pyrimidine and purine nucleoside administration, but not the
corresponding monophosphate nucleotides, adjusted the mtDNA depletion induced by ethidium
bromide in human RRM2B-mutant cells [408]. Similarly, deoxycytidine and tetrahydro uridine were
also able to prevent mtDNA depletion in a cell model of the same syndrome [408]. Recently a mutant
dguok zebrafish line was developed using CRISPR/Cas9 mediated mutagenesis; dguok−/− fishes have
significantly reduced mtDNA levels compared to the wild-type counterpart. In contrast with previous
cell culture studies, when supplemented with only one purine nucleoside (dGuo), mtDNA copy number
in both mutant and wt juvenile animals was significantly reduced, possibly because of nucleotide
pool imbalance. However, a significant increase in liver mtDNA was documented in adult dguok−/−
zebrafish when supplemented with both purine nucleosides. [409].
Recently, an open-label study showed the results of deoxynucleoside monophosphates and
deoxynucleoside administration under a compassionate program to 16 early-onset TK2-patients.
Prolonged survival and improvement of motor abilities compared to untreated patients were recorded.
Four of 5 patients who required enteric nutrition were able to discontinue using the feeding tube;
and 1 of 9 patients who required mechanical ventilation became able to breathe independently.
Out of 8, 3 non-ambulatory patients recovered the ability to walk. Out of 5, 4 patients with enteric
nutrition discontinued the use of the feeding tube. Out of 9, 1 patient who required mechanical
ventilation became able to breathe independently. Although diarrhea was the most common side
effect manifested, discontinuation of the therapy was not necessary. Among 12 other TK2 patients
treated with deoxynucleoside, two adults developed elevated liver enzymes normalized following
discontinuation of therapy [410].
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6. Future Perspectives
6.1. Fetal Gene Therapy
Current prenatal genetic technology can diagnose rare genetic diseases as early as the 12th week
of pregnancy by chorionic villous sampling or from the 16th week by amniocentesis. Advances
in fetal imaging and minimally invasive surgical equipment have also led to the development of
interventional techniques for prenatal treatment of several fetal structural defects, such as congenital
diaphragmatic hernia, myelomeningocele, pulmonary sequestration, hydrothorax, urinary tract
obstruction, fetal tumours and others [411]. Also, intrauterine access to the fetal circulation through
the umbilical vein is a well-described procedure, used to perform ultrasound-guided fetal blood
or platelet transfusions, which are currently the standard of care in cases of fetal anemia and
thrombocytopenia [412]. The option of fetal intervention is offered in specialized centers to reduce
infant mortality and/or morbidity compared to postnatal treatment and, for each type of procedure,
parents are extensively informed about the potential benefits balanced against the risks, which are
mainly fetal death, miscarriage or preterm delivery.
For inherited genetic diseases, In-Utero Gene Therapy (IUGT) offers the potential of prophylaxis
against early, irreversible, and lethal pathological change [413]. From a technical perspective,
potential genetic therapeutic agents can be delivered to the fetus through infusion into the umbilical vein
or via direct injection into the fetal organs. The rationale for IUGT is essentially based on the hypothesis
that anticipating the treatment during fetal life could prevent or mitigate irreversible pathological
changes associated with rare genetic disorders and improve clinical outcomes compared to postnatal
therapy. Possible advantages of IUGT that may overcome some of the limitations encountered in
postnatal gene therapy include: (i) the small fetal size (i.e., smaller area to be treated), (ii) the tolerogenic
fetal immune system, (iii) the presence of highly proliferative and accessible stem/progenitor cells in
multiple organs and, (iv) the ability to treat diseases in which irreversible pathological molecular and
metabolic changes begin before birth [414].
Fetal therapeutic interventions could be especially useful for early-onset PMD in which
mitochondrial dysfunction begins before birth, as the GRACILE syndrome. GRACILE syndrome
initially develops with intrauterine growth retardation. A fatal lactic acidosis arises in the new-borns,
often accompanied by nonspecific aminoaciduria, cholestasis, iron overload, and liver dysfunction [415].
Similarly, mitochondrial dysfunction likely starts before birth in SURF1-associated Leigh syndrome.
Shreds of evidence suggest that SURF1 mutations lead to metabolic impairments in neural progenitor
cells (NPCs), which cannot switch from glycolytic to OXPHOS metabolism, with subsequent aberrant
proliferation and insufficient support for neuronal morphogenesis [416]. A similar neuronal impairment
was reported in a SURF1 ko pig model [417]. Cerebral organoids from LS patients carrying MT-ATP6
mutations also showed defective corticogenesis and suggest pre-natal impairment [418]. These findings
suggest that OXPHOS defect could impair the NSC cellular metabolism in the early phase of the
development leading to the onset of the neurological phenotypes; so prenatal intervention for pediatric
PMD may be crucial for amelioration of the clinical course of the disease.
Fetal gene therapy may provide an alternative therapeutic approach for inherited diseases leading
to early death or lifelong irreversible damage. Due to the lack of PMD-specific, fetal therapeutic
approaches, curative strategies proposed for other genetic diseases should be considered. A recent
study investigated the efficacy of human survival motor neuron (hSMN) gene expression after IU
delivery in SMA mouse embryos. In the first part of the research report, authors showed that
IU-intracerebroventricular injection of adeno-associated virus serotype-9 (AAV9)-EGFP led to an
extensive expression of EGFP protein in different parts of the CNS with a significant number of
transduced NSCs. SMA mouse fetuses receiving a single i.c.v. injection of a single-stranded or
self-complementary AAV9-SMN vector extended their lifespan of 93 (median of 63) or 171 (median 105)
days. Both muscle pathology and motor neuron survival improved upon treatments, with slightly
better results from scAAV administration [413].
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Additional evidence on the safety and efficacy of IUGT in a mouse model of neuronopathic
Gaucher’s disease were recently provided [419]. Fetal intracranial injection of an AAV9 carrying the
curative gene improved neuronal inflammation and spectacularly increased the mice’s overall survival.
Of note, neonatal treatment did not achieve the same results of fetal therapy.
Maternal safety is a critical consideration in any fetal therapy. Possible maternal exposure to the
viral vectors infused into the fetus should be considered in IUGT. Contact with the viral particles may
result in maternal immune responses to the capsid protein or the recombinant protein, although the
latter is unlikely, as the mother should already be producing—and therefore be tolerant to—the protein
missing in the fetus.
Therapeutic viruses, including the AAV vectors, may undergo random integration in fetuses after
IUGT; however, do evidences of germline integration have been reported. New technologies with
more specific gene editing will possibly minimize off-target events of IUGT in future.
Despite promising preliminary results of IUGT, more experimental evidence on animal models
is needed to demonstrate a significant improvement in the pathological hallmarks and the clinical
course of the disease. Clinical trials involving human pregnancies would subsequently need to be
setup, ensuring accurate monitoring of adverse events and long-term postnatal clinical follow-up.
Randomized controlled trials on IUGT versus postnatal treatment may not be realistic due to the
rarity of the investigated diseases and ethical concerns that may arise from offering randomization for
conditions associated with a very severe if not lethal outcome. Also, rare genetic disorders currently
lack any recommended screening policy in the general low-risk population. Therefore, most of the
patients currently receiving a prenatal diagnosis of PMD have experienced a previously affected
child’s birth. In these cases, prenatal treatment parents could be offered within an experimental trial,
after extensive counselling on the uncertainties regarding the clinical results and after discussion of
other management options, which would be termination of pregnancy or postnatal therapy. It could
be anticipated that the recruitment rate in such a context is likely to be extremely low. However,
multicenter collaborative efforts may allow to collect and analyze a meaningful number of cases using
a pre-defined shared protocol, to provide reliable information on the effects of IUGT on long-term
postnatal development of infants affected by rare genetic disorders.
Ethical issues of fetal gene therapy have been reviewed by MacKenzie and collaborators [420].
Fetal treatment pivots on the concept of non-directive advising, in which the choices of no treatment
and exploratory therapy—with all the conceivable risks and benefits—are rationalized without the
physician’s individual inclination. Rigorous preclinical trials and multidisciplinary debates will
continue to advance the frontiers of fetal therapy, while these and other concerns deserve a continuous
discussion [420].
6.2. Metabolic Rewiring
Pharmacological modulations of neuronal morphogenesis and neuronal maturation of the
immature precursors, the neural stem cells (NSCs) have been proposed as an attractive therapeutic
opportunity to treat several neurological diseases. NSCs require a metabolic shift towards oxidative
phosphorylation during the process of neuronal differentiation [421]. Therefore, OXPHOS defects may
inhibit this shift impairing neuronal differentiation and driving neural stem cells (NSCs) to a proliferative
and less differentiated state [416]. We recently tested inductors of oxidative metabolism (developed and
patented by Professional Dietetics, IT) composed of TCA cycle intermediates, specific amino acids,
and co-factors that helped enhance mitochondrial function in different in vitro and in vivo models.
Supplementing wild-type NSC-culture medium with these compounds during the differentiation
phase enhanced the metabolic shift towards OXPHOS and mitochondrial function of mouse and
human NSCs, improving their full differentiation capacity [422]. Neurons derived from treated-NSC
changed the fission–fusion processing resulting in a mitochondrial elongated phenotype; moreover,
the activation of the mTORC1 pathway with subsequent significant increase of ATP production
was reported. Also, the antioxidant defense system was also triggered by the increase of the
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NRF2 gene expression [422]. We observed similar metabolic and molecular changes in vivo, where
they counteracted the pathological mitochondrial dysfunction occurring during the aging process.
Three-month oral administration of metabolic inductor PD-0E7 (Professional Dietetics, IT) to the
Senescence Accelerated Mouse-Prone 8 (SAMP8) mice significantly improved the sarcopenia and
cognitive decline, enhancing oxidative metabolism by inducing mitochondrial biogenesis and increasing
respiratory efficiency [423]. In particular, we documented a strong shift toward oxidative, COX-positive
fibers and a general increase of the MRC enzymatic activities in the skeletal muscle of the 12-month-old
PD-0E7-supplemented mice, which may explain the preserved physical endurance of the treated
SAMP8 mice [423]. Also, the Opa1 isoforms were significantly increased in the skeletal muscle,
as shown by western blot analysis, and this might support the improved stabilization of the CIII
holocomplex into SCs that was detected by blue native gel electrophoresis (BNGE) analysis [423].
To note, the preserved cognitive function observed in the treated mice correlate with enhancement of
the hippocampal mitochondrial proteostasis and with the upregulation of PITRM1, a mitochondrial
matrix enzyme that digests the mitochondrial targeting sequences (MTS) and the mitochondrial fraction
of amyloid beta [424,425].
Although the molecular mechanisms at the basis of the improvement of mitochondrial functions
by such metabolic modulators were not fully elucidated, it is plausible that supplementation of TCA
cycle intermediates and amino acids would feed the anaplerotic flux sustaining mitochondrial energy
production. In support of this, it has recently been demonstrated that anaplerosis is protective in
OXPHOS-deficient neurons with disruption of the MFN2 gene, and that genetic blockage of the
anaplerotic pathway further exacerbated the neuronal degeneration [426]. To date, triheptanoin
is the only reported example of anaplerotic treatment in patients with very-long-chain acyl-CoA
dehydrogenase (VLCAD) deficiency [61]. Studies of the effects of anaplerotic substrates in PMD should
be encouraged.
7. Conclusions
The extreme clinical, genetic, and biochemical variability of PMD coupled with the low number
of patients and the frequent lack of adequate preclinical models have limited identifying useful clinical
outcomes and the development of effective therapy.
The enhancement of mitochondrial function and ATP production through the pharmacological
stimulation of mitochondrial biogenesis, mitophagy, dynamics, and ROS detoxification using
antioxidants may represent a general strategy to alleviate or at least partially corrected different
clinical outcomes. Although these strategies do not solve the problem at the root, these are, in principle,
adaptable to a large group of mitochondrial diseases and could help improve patients’ everyday quality
of life.
Conclusive cure for mitochondrial disease could be achieved by a precision medicine strategy that
considers individual variability in genes, age, sex, stage of the disease, and tissues compromised for
each patient (Figure 4). Although organ transplantation was already used successfully, cell replacement
and gene therapy are still far to become routine for mitochondrial disease due to technical and
regulatory reasons. However, given the recent exciting progress in gene editing and fetal surgery,
we expect steps forward in the coming decades.
Pharmaceutics 2020, 12, 1083 36 of 63
Pharmaceutics 2020, 12, x 35 of 63 
Pharmaceutics 2020, 12, x; www.mdpi.com/journal/pharmaceutics 
 
Figure 4. Severity of the tissue degeneration increases with age, impacting the efficacy of therapeutic 
interventions. IUFGT: In utero fetal gene therapy; MR: metabolic rewiring; MBP: Molecular Bypass 
Therapy; MAT: Mitochondrial Augmentation Therapy; GT: Gene Therapy; OT: Organ 
Transplantation; CR: Cell Replacement; AHSCT: Allogeneic Hematopoietic Stem Cell 
Transplantation. 
Author Contributions: Conceptualization, E.B. and D.B.; methodology, D.B., E.B., C.L., N.P., A.P., and V.T. 
writing—original draft preparation, D.B., E.B., C.L., N.P., A.P., and V.T.; writing—review and editing, D.B. and 
EB.; visualization, C.L., N.P., A.P., and V.T.; supervision D.B. and E.B.; funding acquisition, D.B. and C.L. All 
authors have read and agreed to the published version of the manuscript. 
Funding: This study was supported by the Italian Ministry of Health (grants RF-2016-02361495, and “Ricerca 
Corrente”). 
Acknowledgments: D.B. acknowledge University of Milan, Grant number: BIOMETRA PSR2019-BRUNETTI; 
C. L.is members of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD). This 
project was carried out in the Center for the Study of Mitochondrial Pediatric Diseases 
(http://www.mitopedia.org) funded by the Mariani Foundation 
Conflicts of Interest: The authors declare no conflict of interest. 
Appendix A 
Table A1. Summary of the therapeutic approaches discussed in this manuscript, with a distinction 
between those that have been tested in pre-clinical models and those that have already been used in 
clinical practice. This table is restricted to therapies used to treat PMD and does not include others 
that, although cited in the text, have not been tested in PMD models/patients. 
Therapy Model Study Ref. 
Strategies to increase ATP levels 
Febuxostat plus 
inosine 
patients with homoplasmic mtDNA 
mutation 
clinical [65] 
patient with mitochondrial diabetes with 
heteroplasmic mutation in tRNA leucine 
1 
clinical [65] 
Pharmacological stimulation of mitochondrial biogenesis 
AICAR mouse models of COX defects pre-clinical [74] 
Figure 4. Severity of the tissue degeneration increases ith age, impacting the efficacy of therapeutic
interventions. IUFGT: In utero fetal gene therapy; MR: metabolic rewiring; MBP: Molecular Bypass
Therapy; MAT: Mitochondrial Augmentation Therapy; GT: Gene Therapy; OT: Organ Transplantation;
CR: Cell Replacement; AHSCT: Allogeneic Hematopoietic Stem Cell Transplantation.
Author Contributions: Conceptualization, E.B. and D.B.; methodology, D.B., E.B., C.L., N.P., A.P., and V.T.
writing—original draft preparation, D.B., E.B., C.L., N.P., A.P., and V.T.; writing—review and editing, D.B. and E.B.;
visualization, C.L., N.P., A.P., and V.T.; supervision D.B. and E.B.; funding acquisition, D.B. and C.L. All authors
have read and agree to the published version of the manuscript.
Funding: This study was supported by the Italian Ministry of Health (grants RF-2016-023 1495, and “Ricerca Corrente”).
Acknowledgments: D.B. acknowledge University of Milan, Grant number: BIOMETRA PSR2019-BRUNETTI;
C.L. is memb rs of the European R ference Netw rk for Rare Ne romuscular Diseases (ERN EURO-NMD).
This project was ca ried out in the Cent for th Study f Mitochondrial Pediatric Di eases (http://www.mitopedia.
org) fund d by the Mariani Foundation.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A
Table A1. Summary of the therapeutic approaches discussed in this manuscript, with a distinction
between those that have been tested in pre-clinical odels and those that have already been used in
clinical pr ctice. This table is re tricted to therapies used to treat PMD and does not incl t rs that,
although ci ed in the text, ave not b en tested in PMD models/patients.
Therapy Model Study Ref.
Strategies to increase ATP levels
Febuxostat plus inosine patients with homoplasmic mtDNA mutation clinical [65]
patient with mitochondrial diabetes with
heteroplasmic mutation in tRNA leucine 1
clinical [65]
Pharmacological stimulation of mitochondrial biogenesis
AICAR
mouse models of COX defects pre-clinical [74]
mouse model Cox10-Mef2c-Cre pre-clinical [82]
CI deficient cells (NDUFS2, NDUFS4,
NDUFAF4, C20ORF7, FOXRED1, NDUFA12L)
pre-clinical [83]
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Table A1. Cont.
Therapy Model Study Ref.
Bezafibrate and other
PPAR agonists
MRC-deficient patients’ fibroblasts pre-clinical [87]
SCO2 mutant fibroblasts pre-clinical [88]
DNM1L mutant cells pre-clinical [89]
mouse models of COX defects pre-clinical [74]
Deletor mouse pre-clinical [90]
Mutator mouse pre-clinical [91]
patients with MM clinical [92]
NAD+ precursors
Sco2 ko mouse pre-clinical [81]
Deletor mouse pre-clinical [106]
GBA-PD Drosophila melanogaster pre-clinical [107]
Ndufs4 ko mice pre-clinical [108]
Niacin patients with MM clinical (NCT03973203) [109]
I-BET 525762A cybrids carrying 3796A>G mutation pre-clinical [110]
Polyphenols and other Pharmacognostic Products
Resveratrol fibroblasts from MT-TL1, MT-TK,
MT-ATP6-patients
pre-clinical [125]
Curcumin LHON patients clinical (NCT00528151) unpublished
Pharmacological modulation of the NO/cGMP/PKG pathway
L-arginine and L-citrulline
MELAS patients clinical (open-label trial) [162,164,168]
MELAS patients clinical (open-label trial) [165]
various PMD patients clinical (NCT02809170) unpublished




NPCs with homoplasmic mutation in MT-ATP6 pre-clinical [176]
LHON clinical (case report) [179]
Antioxidant
Glutathione
MM patients clinical (double-blind
cross-over study)
[188]
fibroblasts of patients carrying the m.3243A>G
and m.8344A>G mutations
pre-clinical [189]
Cysteamine C. elegans model of CI defect, FBXL4 mutant
human fibroblast, and zebrafish models of




PMD paediatric patients clinical (NCT02023866) unpublished
N-acetylcysteine Ethe1 mouse model pre-clinical [195]
ETHE1 patients clinical (compassionate
use)
[198–200]





Vitamin C and K PMD patients Clinical [208–210]
Vitamin E fibroblasts from patients with CI defect pre-clinical [211,212]
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Table A1. Cont.
Therapy Model Study Ref.
Coenzyme Q10
MERRF cells pre-clinical [220]
KSS patients clinical [221]
KSS patents and other MM with CPEO clinical [222–224,226,
228,230]
patient with mitochondrial
encephalomyopathy with COX deficiency
clinical [225]
patients with mitochondrial cytopathies clinical [227]
PMD patients clinical [229]










PMD paediatric patients clinical (NCT00432744) [234]
Idebenone
fibroblasts from LHON patients pre-clinical [237,238]
mouse model of LHON pre-clinical [239]
85 LHON patients with to m.3460G>A,




subset of LHON patients from RHODOS study clinical (RHODOS-OFU,
NCT01421381)
[242]
patient with TXN2 mutation [243]
Opa1 mutant mice pre-clinical [245]
seven DOA patients clinial [246]





PMD patients clinical [259]




children with mitochondrial encephalopathy Clinical [261]
one patient with Leigh syndrome due to ND3
mutation
Clinical [262]
patients with LHON clinical (open-label trial) [263]
patients with Leigh syndrome clinical (NCT02352896) unpublished
PMD paediatric patients clinical (NCT01642056) unpublished




cellular models of CI defects pre-clinical [268]
Ndufs4 ko mouse model pre-clinical [269,270]
patients with m.3242A>G mutation clinical (KHENERGY
STUDY, NCT02909400)
[272]
patients with MELAS clinical (KHENERGYZE
Study, NCT04165239)
[273]
SKQ1 Mutator mouse pre-clinical [281]
Pharmacological modulation of mitochondrial dynamics
Cytotoxic Necrotizing
Factor 1 (CNF1)
MERRF fibroblasts pre-clinical [300]
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Therapy Model Study Ref.
Pharmacological protection of cardiolipin
Elamipretide
patients with primary mitochondrial myopathy
(MM)
clinical (NCT03323749) [310]
Barth syndrome clinical (NCT03098797) unpublished
LHON patients clinical (NCT02693119) unpublished
age-related macular degeneration (AMD) with
non-central geographic atrophy
clinical (NCT03891875) unpublished
Pharmacological modulation of autophagy
Rapamycin
Ndufs4 ko mouse pre-clinical [313]
muscle-specific Cox15 ko mouse pre-clinical [314]
ND2-deficient Drosophila model of LS pre-clinical [315]
MT-ATP6-mutant, iPSCs-derived neurons pre-clinical [316]
gas-1 (fc21) nematodes pre-clinical [317]
mice with CoQ10 deficiency pre-clinical [320]
TwKOastro mice pre-clinical [59]
Everolimus (rapamycin
analogue)
MELAS patients clinical (NCT03747328) [318]
children affected by Leigh disease or MELAS Clinical [319]
Bypassing cI-cIII-cIV defects with alternative enzymes
NDI1 CI deficiency in Drosophila melanogaster pre-clinical [324]
mouse model of LHON pre-clinical [238]
mouse model of Leigh syndrome pre-clinical [239]
AOX, NDI1 ρ0 mouse cells pre-clinical [325]
AOX CIII-IV deficiencies in human cells pre-clinical [326]
CIV deficient Drosophila melanogaster pre-clinical [327]
Bcs1lp.S78G knock-in mice pre-clinical [330,331]
Acta-Cox15 ko model pre-clinical [332]
NDH-2 human CI deficient fibroblasts pre-clinical [333]
Personalized therapies for mtDNA disorders
Mitochondrial donation:
maternal spindle transfer
legally approved for use in the U.K clinical [343]
rhesus macaques pre-clinical [344]






Delivery of nucleic acids to
the mitochondria
patient’s cell with a G625A heteroplasmic
mutation in the tRNAPhe
pre-clinical [355]
ND3 mutant fibroblasts pre-clinical [356]
MERFF and KSS cybrids pre-clinical [354]
Heteroplasmic shift various cells with heteroplasmic mutation pre-clinical [359–361]
mouse model of heteroplasmic PMD pre-clinical [366,367]
Allotopic gene expression
cybrids with m.8993T>G mutation pre-clinical [369]
rat model of LHON pre-clinical [370]





children with Pearson syndrome clinical Unpublished
children with KSS or Pearson Syndrome clinical (NCT03384420) unpublished
KSS patient clinical [375]
Pharmaceutics 2020, 12, 1083 40 of 63
Table A1. Cont.
Therapy Model Study Ref.
Precision medicine approaches for PMD caused by nuclear defects
Gene therapy approaches
Ant1 ko mouse model pre-clinical [381]
Tymp ko mouse model pre-clinical [390]
Ethe1 ko mouse model pre-clinical [389]
Ndufs4 mouse model pre-clinical [391]
Mpv17 ko mouse model pre-clinical [58]
mouse model of Leigh syndrome pre-clinical [382]
Liver transplantation
PMD patients clinical [385]
DGUOK-deficient patients clinical [386]
25-year-old MNGIE patient clinical [395]
ETHE1 patients clinical [396,397]
Cell replacement MNGIE patients clinical [400,401]
Molecular bypass therapy
in disorders of mtDNA
instability
Tk2 mouse model pre-clinical [405–407]
DGUOK mutant fibroblasts pre-clinical [404]
RRM2B mutant fibroblasts pre-clinical [408]
dguok−/− zebrafish pre-clinical [409]
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Tyynismaa, H.; Suomalainen, A. Ketogenic diet slows down mitochondrial myopathy progression in mice.
Hum. Mol. Genet. 2010, 19, 1974–1984. [CrossRef] [PubMed]
56. Purhonen, J.; Rajendran, J.; Mörgelin, M.; Uusi-Rauva, K.; Katayama, S.; Krjutskov, K.; Einarsdottir, E.;
Velagapudi, V.; Kere, J.; Jauhiainen, M.; et al. Ketogenic diet attenuates hepatopathy in mouse model of
respiratory chain complex III deficiency caused by a Bcs1l mutation. Sci. Rep. 2017, 7, 1–16. [CrossRef]
57. Bottani, E.; Giordano, C.; Civiletto, G.; Di Meo, I.; Auricchio, A.; Ciusani, E.; Marchet, S.; Lamperti, C.;
D’Amati, G.; Viscomi, C.; et al. AAV-mediated Liver-specific MPV17 Expression Restores mtDNA Levels
and Prevents Diet-induced Liver Failure. Mol. Ther. 2014, 22, 10–17. [CrossRef]
58. Brunetti, D.; Dusi, S.; Giordano, C.; Lamperti, C.; Morbin, M.; Fugnanesi, V.; Marchet, S.; Fagiolari, G.;
Sibon, O.; Moggio, M.; et al. Pantethine treatment is effective in recovering the disease phenotype induced by
ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain 2014, 137, 57–68.
[CrossRef]
59. Ignatenko, O.; Nikkanen, J.; Kononov, A.; Zamboni, N.; Ince-Dunn, G.; Suomalainen, A. Mitochondrial
spongiotic brain disease: Astrocytic stress and harmful rapamycin and ketosis effect. Life Sci. Alliance 2020,
3, e202000797. [CrossRef]
60. Ahola, S.; Auranen, M.; Isohanni, P.; Niemisalo, S.; Urho, N.; Buzkova, J.; Velagapudi, V.; Lundbom, N.;
Hakkarainen, A.; Muurinen, T.; et al. Modified Atkins diet induces subacute selective ragged-red-fiber lysis
in mitochondrial myopathy patients. EMBO Mol. Med. 2016, 8, 1234–1247. [CrossRef]
61. Roe, C.R.; Sweetman, L.; Roe, D.S.; David, F.; Brunengraber, H. Treatment of cardiomyopathy and
rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride.
J. Clin. Investig. 2002, 110, 259–269. [CrossRef] [PubMed]
62. Jain, I.H.; Zazzeron, L.; Goli, R.; Alexa, K.; Schatzman-Bone, S.; Dhillon, H.; Goldberger, O.; Peng, J.;
Shalem, O.; Sanjana, N.E.; et al. Hypoxia as a therapy for mitochondrial disease. Science 2016, 352, 54–61.
[CrossRef] [PubMed]
63. Ferrari, M.; Jain, I.H.; Goldberger, O.; Rezoagli, E.; Thoonen, R.; Cheng, K.-H.; Sosnovik, D.E.;
Scherrer-Crosbie, M.; Mootha, V.K.; Zapol, W.M. Hypoxia treatment reverses neurodegenerative disease
in a mouse model of Leigh syndrome. Proc. Natl. Acad. Sci. USA 2017, 114, E4241–E4250. [CrossRef] [PubMed]
64. Kamatani, N.; Hashimoto, M.; Sakurai, K.; Gokita, K.; Yoshihara, J.; Sekine, M.; Mochii, M.-A.; Fukuuchi, T.;
Yamaoka, N.; Kaneko, K. Clinical studies on changes in purine compounds in blood and urine by the
simultaneous administration of febuxostat and inosine, or by single administration of each. Gout Nucleic
Acid Metab. 2017, 41, 171–181. [CrossRef]
65. Kamatani, N.; Kushiyama, A.; Toyo-Oka, L.; Toyo-Oka, T. Treatment of two mitochondrial disease patients
with a combination of febuxostat and inosine that enhances cellular ATP. J. Hum. Genet. 2019, 64, 351–353.
[CrossRef]
66. Rossignol, R.; Faustin, B.; Rocher, C.; Malgat, M.; Mazat, J.-P.; Letellier, T. Mitochondrial threshold effects.
Biochem. J. 2003, 370, 751–762. [CrossRef]
67. Lee, H.-C.; Wei, Y.-H. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells
under oxidative stress. Int. J. Biochem. Cell Biol. 2005, 37, 822–834. [CrossRef]
68. Gleyzer, N.; Vercauteren, K.; Scarpulla, R.C. Control of Mitochondrial Transcription Specificity Factors
(TFB1M and TFB2M) by Nuclear Respiratory Factors (NRF-1 and NRF-2) and PGC-1 Family Coactivators.
Mol. Cell. Biol. 2005, 25, 1354–1366. [CrossRef]
Pharmaceutics 2020, 12, 1083 44 of 63
69. Schreiber, S.N.; Emter, R.; Hock, M.B.; Knutti, D.; Cardenas, J.; Podvinec, M.; Oakeley, E.J.; Kralli, A.
The estrogen-related receptor (ERR) functions in PPAR coactivator 1 (PGC-1)-induced mitochondrial
biogenesis. Proc. Natl. Acad. Sci. USA 2004, 101, 6472–6477. [CrossRef]
70. Wu, Z.; Puigserver, P.; Andersson, U.; Zhang, C.; Adelmant, G.; Mootha, V.; Troy, A.; Cinti, S.; Lowell, B.;
Scarpulla, R.C.; et al. Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the
Thermogenic Coactivator PGC-1. Cell 1999, 98, 115–124. [CrossRef]
71. Mullur, R.; Liu, Y.-Y.; Brent, G.A. Thyroid Hormone Regulation of Metabolism. Physiol. Rev. 2014, 94, 355–382.
[CrossRef] [PubMed]
72. Scarpulla, R.C.; Vega, R.B.; Kelly, D.P. Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol.
Metab. 2012, 23, 459–466. [CrossRef] [PubMed]
73. Lin, J.; Wu, H.; Tarr, P.T.; Zhang, C.-Y.; Wu, Z.; Boss, O.; Michael, L.F.; Puigserver, P.; Isotani, E.; Olson, E.N.; et al.
Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres. Nat. Cell Biol. 2002,
418, 797–801. [CrossRef] [PubMed]
74. Viscomi, C.; Bottani, E.; Civiletto, G.; Cerutti, R.; Moggio, M.; Fagiolari, G.; Schon, E.A.; Lamperti, C.;
Zeviani, M. In Vivo Correction of COX Deficiency by Activation of the AMPK/PGC-1α Axis. Cell Metab.
2011, 14, 80–90. [CrossRef] [PubMed]
75. Puigserver, P.; Wu, Z.; Park, C.W.; Graves, R.; Wright, M.; Spiegelman, B.M. A Cold-Inducible Coactivator of
Nuclear Receptors Linked to Adaptive Thermogenesis. Cell 1998, 92, 829–839. [CrossRef]
76. Geng, T.; Li, P.; Okutsu, M.; Yin, X.; Kwek, J.; Zhang, M.; Yan, Z. PGC-1α plays a functional role in
exercise-induced mitochondrial biogenesis and angiogenesis but not fiber-type transformation in mouse
skeletal muscle. Am. J. Physiol. Physiol. 2010, 298, C572–C579. [CrossRef]
77. Jäger, S.; Handschin, C.; St.-Pierre, J.; Spiegelman, B.M. AMP-activated protein kinase (AMPK) action in
skeletal muscle via direct phosphorylation of PGC-1. Proc. Natl. Acad. Sci. USA 2007, 104, 12017–12022.
[CrossRef]
78. Gerhart-Hines, Z.; Rodgers, J.T.; Bare, O.; Lerin, C.; Kim, S.-H.; Mostoslavsky, R.; Alt, F.W.; Wu, Z.; Puigserver, P.
Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α. EMBO J.
2007, 26, 1913–1923. [CrossRef]
79. Hardie, D.G. AMP-activated protein kinase–an energy sensor that regulates all aspects of cell function.
Genes Dev. 2011, 25, 1895–1908. [CrossRef]
80. Cantó, C.; Auwerx, J. PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure.
Curr. Opin. Lipidol. 2009, 20, 98–105. [CrossRef]
81. Cerutti, R.; Pirinen, E.; Lamperti, C.; Marchet, S.; Sauve, A.A.; Li, W.; Leoni, V.; Schon, E.A.; Dantzer, F.;
Auwerx, J.; et al. NAD+-Dependent Activation of Sirt1 Corrects the Phenotype in a Mouse Model of
Mitochondrial Disease. Cell Metab. 2014, 19, 1042–1049. [CrossRef] [PubMed]
82. Peralta, S.; Garcia, S.; Yin, H.Y.; Arguello, T.; Diaz, F.; Moraes, C.T. Sustained AMPK activation improves
muscle function in a mitochondrial myopathy mouse model by promoting muscle fiber regeneration.
Hum. Mol. Genet. 2016, 25, 3178–3191. [CrossRef] [PubMed]
83. Saada, A.; Dan, P.; Weissman, S.; Link, G.; Wikstrom, J.D.; Saada, A. Screening for Active Small Molecules in
Mitochondrial Complex I Deficient Patient’s Fibroblasts, Reveals AICAR as the Most Beneficial Compound.
PLoS ONE 2011, 6, e26883. [CrossRef]
84. Lefebvre, P.; Chinetti, G.; Fruchart, J.-C.; Staels, B. Sorting out the roles of PPAR in energy metabolism and
vascular homeostasis. J. Clin. Investig. 2006, 116, 571–580. [CrossRef]
85. Kersten, S. Integrated physiology and systems biology of PPARα. Mol. Metab. 2014, 3, 354–371. [CrossRef]
86. Djouadi, F.; Bastin, J. Mitochondrial Genetic Disorders: Cell Signaling and Pharmacological Therapies. Cells
2019, 8, 289. [CrossRef]
87. Bastin, J.; Aubey, F.; Rötig, A.; Munnich, A.; Djouadi, F. Activation of Peroxisome Proliferator-Activated
Receptor Pathway Stimulates the Mitochondrial Respiratory Chain and Can Correct Deficiencies in Patients’
Cells Lacking Its Components. J. Clin. Endocrinol. Metab. 2008, 93, 1433–1441. [CrossRef]
88. Casarin, A.; Giorgi, G.; Pertegato, V.; Siviero, R.; Cerqua, C.; Doimo, M.; Basso, G.; Sacconi, S.; Cassina, M.;
Rizzuto, R.; et al. Copper and bezafibrate cooperate to rescue cytochrome c oxidase deficiency in cells of
patients with sco2 mutations. Orphanet J. Rare Dis. 2012, 7, 21. [CrossRef]
89. Douiev, L.; Sheffer, R.; Horvath, G.A.; Saada, A. Bezafibrate Improves Mitochondrial Fission and Function in
DNM1L-Deficient Patient Cells. Cells 2020, 9, 301. [CrossRef]
Pharmaceutics 2020, 12, 1083 45 of 63
90. Yatsuga, S.; Suomalainen, A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice.
Hum. Mol. Genet. 2011, 21, 526–535. [CrossRef]
91. Dillon, L.M.; Hida, A.; Garcia, S.; Prolla, T.A.; Moraes, C.T. Long-Term Bezafibrate Treatment Improves Skin
and Spleen Phenotypes of the mtDNA Mutator Mouse. PLoS ONE 2012, 7, e44335. [CrossRef] [PubMed]
92. Steele, H.; Gomez-Duran, A.; Pyle, A.; Hopton, S.; Newman, J.; Stefanetti, R.J.; Charman, S.J.; Parikh, J.D.;
He, L.; Viscomi, C.; et al. Metabolic effects of bezafibrate in mitochondrial disease. EMBO Mol. Med. 2020,
12, e11589. [CrossRef] [PubMed]
93. Hondares, E.; Mora, O.; Yubero, P.; De La Concepción, M.R.; Iglesias, R.; Giralt, M.; Villarroya, F.
Thiazolidinediones and Rexinoids Induce Peroxisome Proliferator-Activated Receptor-Coactivator (PGC)-1α
Gene Transcription: An Autoregulatory Loop Controls PGC-1α Expression in Adipocytes via Peroxisome
Proliferator-Activated Receptor-γ Coactivation. Endocrinology 2006, 147, 2829–2838. [CrossRef] [PubMed]
94. Miglio, G.; Rosa, A.C.; Rattazzi, L.; Collino, M.; Lombardi, G.; Fantozzi, R. PPARγ stimulation promotes
mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem. Int. 2009,
55, 496–504. [CrossRef]
95. Wilson-Fritch, L.; Burkart, A.; Bell, G.; Mendelson, K.; Leszyk, J.D.; Nicoloro, S.M.; Czech, M.P.; Corvera, S.
Mitochondrial Biogenesis and Remodeling during Adipogenesis and in Response to the Insulin Sensitizer
Rosiglitazone. Mol. Cell. Biol. 2003, 23, 1085–1094. [CrossRef]
96. Rong, J.X.; Klein, J.-L.D.; Qiu, Y.; Xie, M.; Johnson, J.H.; Waters, K.M.; Zhang, V.; Kashatus, J.A.; Remlinger, K.S.;
Bing, N.; et al. Rosiglitazone Induces Mitochondrial Biogenesis in Differentiated Murine 3T3-L1 and
C3H/10T1/2 Adipocytes. PPAR Res. 2011, 2011, 1–11. [CrossRef]
97. Strum, J.C.; Shehee, R.; Virley, D.; Richardson, J.; Mattie, M.; Selley, P.; Ghosh, S.; Nock, C.; Saunders, A.;
Roses, A. Rosiglitazone Induces Mitochondrial Biogenesis in Mouse Brain. J. Alzheimers Dis. 2007, 11, 45–51.
[CrossRef]
98. Andreux, P.A.; Houtkooper, R.H.; Auwerx, J. Pharmacological approaches to restore mitochondrial function.
Nat. Rev. Drug Discov. 2013, 12, 465–483. [CrossRef]
99. Bieganowski, P.; Brenner, C. Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes
Establish a Preiss-Handler Independent Route to NAD+ in Fungi and Humans. Cell 2004, 117, 495–502.
[CrossRef]
100. Cantó, C.; Menzies, K.J.; Auwerx, J. NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing
Act between Mitochondria and the Nucleus. Cell Metab. 2015, 22, 31–53. [CrossRef]
101. Bai, P.; Cantó, C.; Oudart, H.; Brunyánszki, A.; Cen, Y.; Thomas, C.; Yamamoto, H.; Huber, A.; Kiss, B.;
Houtkooper, R.H.; et al. PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation.
Cell Metab. 2011, 13, 461–468. [CrossRef] [PubMed]
102. Pirinen, E.; Cantó, C.; Jo, Y.S.; Morato, L.; Zhang, H.; Menzies, K.J.; Williams, E.G.; Mouchiroud, L.;
Moullan, N.; Hagberg, C.; et al. Pharmacological Inhibition of Poly(ADP-Ribose) Polymerases Improves
Fitness and Mitochondrial Function in Skeletal Muscle. Cell Metab. 2014, 19, 1034–1041. [CrossRef] [PubMed]
103. Katsyuba, E.; Mottis, A.; Zietak, M.; De Franco, F.; Van Der Velpen, V.; Gariani, K.; Ryu, D.; Cialabrini, L.;
Matilainen, O.; Liscio, P.; et al. De novo NAD+ synthesis enhances mitochondrial function and improves
health. Nature 2018, 563, 354–359. [CrossRef] [PubMed]
104. Belenky, P.; Bogan, K.L.; Brenner, C. NAD+ metabolism in health and disease. Trends Biochem. Sci. 2007,
32, 12–19. [CrossRef]
105. Pirinen, E.; Auranen, M.; Khan, N.A.; Brilhante, V.; Urho, N.; Pessia, A.; Hakkarainen, A.; Kuula, J.;
Heinonen, U.; Schmidt, M.S.; et al. Niacin Cures Systemic NAD+ Deficiency and Improves Muscle
Performance in Adult-Onset Mitochondrial Myopathy. Cell Metab. 2020, 31, 1078–1090.e5. [CrossRef]
106. Khan, N.A.; Auranen, M.; Paetau, I.; Pirinen, E.; Euro, L.; Forsström, S.; Pasila, L.; Velagapudi, V.; Carroll, C.J.;
Auwerx, J.; et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B 3.
EMBO Mol. Med. 2014, 6, 721–731. [CrossRef]
107. Schöndorf, D.C.; Ivanyuk, D.; Baden, P.; Sanchez-Martinez, A.; De Cicco, S.; Yu, C.; Giunta, I.; Schwarz, L.K.; Di
Napoli, G.; Panagiotakopoulou, V.; et al. The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial
Defects and Neuronal Loss in iPSC and Fly Models of Parkinson’s Disease. Cell Rep. 2018, 23, 2976–2988.
[CrossRef]
108. Lee, C.F.; Caudal, A.; Abell, L.; Gowda, G.A.N.; Tian, R. Targeting NAD+ Metabolism as Interventions for
Mitochondrial Disease. Sci. Rep. 2019, 9, 1–10. [CrossRef]
Pharmaceutics 2020, 12, 1083 46 of 63
109. Airhart, S.E.; Shireman, L.M.; Risler, L.J.; Anderson, G.D.; Gowda, G.A.N.; Raftery, D.; Tian, R.; Shen, D.D.;
O’Brien, K.D. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement
nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS ONE 2017,
12, e0186459. [CrossRef]
110. Barrow, J.J.; Balsa, E.; Verdeguer, F.; Tavares, C.D.J.; Soustek, M.S.; Hollingsworth, L.R.; Jedrychowski, M.;
Vogel, R.; Paulo, J.A.; Smeitink, J.; et al. Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by
Mitochondrial Disease Complex I Mutations. Mol. Cell 2016, 64, 163–175. [CrossRef]
111. Baratta, M.G.; Schinzel, A.C.; Zwang, Y.; Bandopadhayay, P.; Bowman-Colin, C.; Kutt, J.; Curtis, J.; Piao, H.;
Wong, L.C.; Kung, A.L.; et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4,
is a potential therapeutic target in ovarian carcinoma. Proc. Natl. Acad. Sci. USA 2015, 112, 232–237.
[CrossRef] [PubMed]
112. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.;
Kisielewski, A.; Zhang, L.-L.; et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae
lifespan. Nat. Cell Biol. 2003, 425, 191–196. [CrossRef] [PubMed]
113. Price, N.L.; Gomes, A.P.; Ling, A.J.; Duarte, F.V.; Martin-Montalvo, A.; North, B.J.; Agarwal, B.; Ye, L.;
Ramadori, G.; Teodoro, J.S.; et al. SIRT1 Is Required for AMPK Activation and the Beneficial Effects of
Resveratrol on Mitochondrial Function. Cell Metab. 2012, 15, 675–690. [CrossRef] [PubMed]
114. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.;
Lambert, P.; Elliott, P.; et al. Resveratrol Improves Mitochondrial Function and Protects against Metabolic
Disease by Activating SIRT1 and PGC-1α. Cell 2006, 127, 1109–1122. [CrossRef] [PubMed]
115. Cantó, C.; Gerhart-Hines, Z.; Feige, J.N.; Lagouge, M.; Noriega, L.; Milne, J.C.; Elliott, P.J.; Puigserver, P.;
Auwerx, J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.
Nat. Cell Biol. 2009, 458, 1056–1060. [CrossRef] [PubMed]
116. Dasgupta, B.; Milbrandt, J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA
2007, 104, 7217–7222. [CrossRef]
117. Borra, M.T.; Smith, B.C.; Denu, J.M. Mechanism of Human SIRT1 Activation by Resveratrol. J. Biol. Chem.
2005, 280, 17187–17195. [CrossRef]
118. Beher, D.; Wu, J.; Cumine, S.; Kim, K.W.; Lu, S.-C.; Atangan, L.; Wang, M. Resveratrol is Not a Direct Activator
of SIRT1 Enzyme Activity. Chem. Biol. Drug Des. 2009, 74, 619–624. [CrossRef]
119. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E.A.; Caldwell, S.D.; Napper, A.; Curtis, R.;
Distefano, P.S.; Fields, S.; et al. Substrate-specific Activation of Sirtuins by Resveratrol. J. Biol. Chem. 2005,
280, 17038–17045. [CrossRef]
120. Um, J.-H.; Park, S.-J.; Kang, H.; Yang, S.; Foretz, M.; McBurney, M.W.; Kim, M.K.; Viollet, B.; Chung, J.H.
AMP-Activated Protein Kinase-Deficient Mice Are Resistant to the Metabolic Effects of Resveratrol. Diabetes
2010, 59, 554–563. [CrossRef]
121. Hou, X.; Xu, S.; Maitland-Toolan, K.A.; Sato, K.; Jiang, B.; Ido, Y.; Lan, F.; Walsh, K.; Wierzbicki, M.;
Verbeuren, T.J.; et al. SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated
Protein Kinase. J. Biol. Chem. 2008, 283, 20015–20026. [CrossRef] [PubMed]
122. Lan, F.; Cacicedo, J.M.; Ruderman, N.; Ido, Y. SIRT1 Modulation of the Acetylation Status,
Cytosolic Localization, and Activity of LKB1. J. Biol. Chem. 2008, 283, 27628–27635. [CrossRef] [PubMed]
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